1
|
Adachi M, Fujioka T, Ishiba T, Nara M, Maruya S, Hayashi K, Kumaki Y, Yamaga E, Katsuta L, Hao D, Hartman M, Mengling F, Oda G, Kubota K, Tateishi U. AI Use in Mammography for Diagnosing Metachronous Contralateral Breast Cancer. J Imaging 2024; 10:211. [PMID: 39330431 DOI: 10.3390/jimaging10090211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2024] [Revised: 08/14/2024] [Accepted: 08/22/2024] [Indexed: 09/28/2024] Open
Abstract
Although several studies have been conducted on artificial intelligence (AI) use in mammography (MG), there is still a paucity of research on the diagnosis of metachronous bilateral breast cancer (BC), which is typically more challenging to diagnose. This study aimed to determine whether AI could enhance BC detection, achieving earlier or more accurate diagnoses than radiologists in cases of metachronous contralateral BC. We included patients who underwent unilateral BC surgery and subsequently developed contralateral BC. This retrospective study evaluated the AI-supported MG diagnostic system called FxMammo™. We evaluated the capability of FxMammo™ (FathomX Pte Ltd., Singapore) to diagnose BC more accurately or earlier than radiologists' assessments. This evaluation was supplemented by reviewing MG readings made by radiologists. Out of 1101 patients who underwent surgery, 10 who had initially undergone a partial mastectomy and later developed contralateral BC were analyzed. The AI system identified malignancies in six cases (60%), while radiologists identified five cases (50%). Notably, two cases (20%) were diagnosed solely by the AI system. Additionally, for these cases, the AI system had identified malignancies a year before the conventional diagnosis. This study highlights the AI system's effectiveness in diagnosing metachronous contralateral BC via MG. In some cases, the AI system consistently diagnosed cancer earlier than radiological assessments.
Collapse
Affiliation(s)
- Mio Adachi
- Department of Breast Surgery, Tokyo Medical and Dental University Hospital, Tokyo 113-8510, Japan
| | - Tomoyuki Fujioka
- Department of Diagnostic Radiology, Tokyo Medical and Dental University Hospital, Tokyo 113-8510, Japan
| | - Toshiyuki Ishiba
- Department of Breast Surgery, Tokyo Medical and Dental University Hospital, Tokyo 113-8510, Japan
| | - Miyako Nara
- Ohtsuka Breast Care Clinic, Tokyo 121-0813, Japan
| | - Sakiko Maruya
- Department of Breast Surgery, Tokyo Medical and Dental University Hospital, Tokyo 113-8510, Japan
| | - Kumiko Hayashi
- Department of Breast Surgery, Tokyo Medical and Dental University Hospital, Tokyo 113-8510, Japan
| | - Yuichi Kumaki
- Department of Breast Surgery, Tokyo Medical and Dental University Hospital, Tokyo 113-8510, Japan
| | - Emi Yamaga
- Department of Diagnostic Radiology, Tokyo Medical and Dental University Hospital, Tokyo 113-8510, Japan
| | - Leona Katsuta
- Department of Diagnostic Radiology, Tokyo Medical and Dental University Hospital, Tokyo 113-8510, Japan
| | - Du Hao
- Saw Swee Hock School of Public Health, National University of Singapore, National University Health System, Singapore 119074, Singapore
| | - Mikael Hartman
- Saw Swee Hock School of Public Health, National University of Singapore, National University Health System, Singapore 119074, Singapore
- Department of Surgery, National University Hospital, National University Health System, Singapore 119074, Singapore
- Institute of Data Science, National University of Singapore, Singapore 117597, Singapore
| | - Feng Mengling
- Saw Swee Hock School of Public Health, National University of Singapore, National University Health System, Singapore 119074, Singapore
- Institute of Data Science, National University of Singapore, Singapore 117597, Singapore
| | - Goshi Oda
- Department of Breast Surgery, Tokyo Medical and Dental University Hospital, Tokyo 113-8510, Japan
| | - Kazunori Kubota
- Department of Radiology, Dokkyo Medical University Saitama Medical Center, Saitama 343-8555, Japan
| | - Ukihide Tateishi
- Department of Diagnostic Radiology, Tokyo Medical and Dental University Hospital, Tokyo 113-8510, Japan
| |
Collapse
|
2
|
Bhimani F, McEvoy M, Gupta A, Pastoriza J, Shihabi A, Basavatia A, Tomé WA, Fox J, Mehta K, Feldman S. Case Report: Bilateral targeted intraoperative radiotherapy: a safe and effective alternative for synchronous bilateral breast cancer. Front Oncol 2023; 13:1276766. [PMID: 37941541 PMCID: PMC10628514 DOI: 10.3389/fonc.2023.1276766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2023] [Accepted: 10/13/2023] [Indexed: 11/10/2023] Open
Abstract
Background The incidence of bilateral breast cancer (BBC) ranges from 1.4% to 11.8%. BBC irradiation is a challenge in current clinical practice due to the large target volume that must be irradiated while minimizing the dose to critical organs. Supine or prone breast techniques can be used, with the latter providing better organ sparing; both, however, result in lengthy treatment times. The use of Intra-operative radiotherapy (IORT) in breast cancer patients who choose breast conservation has been highlighted in previous studies, but there is a scarcity of literature analyzing the utility and applicability of IORT in BBC. This case series aims to highlight the applicability of administering bilateral IORT in patients with BBC. Case reports Five patients with bilateral early-stage breast cancer (or DCIS) were treated with breast-conserving surgery followed by bilateral IORT. Of the 10 breast cancers, 8 were diagnosed as either DCIS or IDC, while the other 2 were diagnosed as invasive lobular carcinoma and invasive carcinoma, respectively. During surgery, all patients received bilateral IORT. Furthermore, 1 patient received external beam radiation therapy after her final pathology revealed grade 3 DCIS. The IORT procedure was well tolerated by all five patients, and all patients received aromatase inhibitors as adjuvant therapy. Additionally, none of these patients showed evidence of disease after a 36-month median follow-up. Conclusion Our findings demonstrate the successful use of IORT for BCS in patients with BBC. Furthermore, none of the patients in our study experienced any complications, suggesting the feasibility of the use of IORT in BBC. Considering the benefits of improved patient compliance and a reduced number of multiple visits, IORT may serve as an excellent patient-centered alternative for BBC. Future studies are recommended to reinforce the applicability of IORT in patients with BBC.
Collapse
Affiliation(s)
- Fardeen Bhimani
- Breast Surgery Division, Department of Surgery, Montefiore Medical Center, Montefiore Einstein Center for Cancer Care, Bronx, NY, United States
| | - Maureen McEvoy
- Breast Surgery Division, Department of Surgery, Montefiore Medical Center, Montefiore Einstein Center for Cancer Care, Bronx, NY, United States
| | - Anjuli Gupta
- Breast Surgery Division, Department of Surgery, Montefiore Medical Center, Montefiore Einstein Center for Cancer Care, Bronx, NY, United States
| | - Jessica Pastoriza
- Breast Surgery Division, Department of Surgery, Montefiore Medical Center, Montefiore Einstein Center for Cancer Care, Bronx, NY, United States
| | - Areej Shihabi
- Breast Surgery Division, Department of Surgery, Montefiore Medical Center, Montefiore Einstein Center for Cancer Care, Bronx, NY, United States
| | - Amar Basavatia
- Department of Radiation Oncology, Montefiore Medical Center, Bronx, NY, United States
| | - Wolfgang A. Tomé
- Department of Radiation Oncology, Montefiore Medical Center, Bronx, NY, United States
| | - Jana Fox
- Department of Radiation Oncology, Montefiore Medical Center, Bronx, NY, United States
| | - Keyur Mehta
- Department of Radiation Oncology, Montefiore Medical Center, Bronx, NY, United States
| | - Sheldon Feldman
- Breast Surgery Division, Department of Surgery, Montefiore Medical Center, Montefiore Einstein Center for Cancer Care, Bronx, NY, United States
| |
Collapse
|
3
|
Bertani V, Berger N, Eberhard M, Lång K, Urbani M, La Grassa M, Balestreri L, Boss A, Frauenfelder T, Marcon M. Mammographic calcifications undergoing percutaneous biopsy: outcome in women with and without a personal history of breast cancer. LA RADIOLOGIA MEDICA 2023; 128:149-159. [PMID: 36598734 PMCID: PMC9938807 DOI: 10.1007/s11547-022-01583-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Accepted: 12/20/2022] [Indexed: 01/05/2023]
Abstract
PURPOSE To compare the positive predictive values (PPVs) of BI-RADS categories used to assess pure mammographic calcifications in women with and without a previous history of breast cancer (PHBC). MATERIALS AND METHODS In this retrospective study, all consecutive pure mammographic calcifications (n = 320) undergoing a stereotactic biopsy between 2016 and 2018 were identified. Mammograms were evaluated in consensus by two radiologists according to BI-RADS and blinded to patient history and pathology results. Final pathologic results were used as the standard of reference. PPV of BI-RADS categories were compared between the two groups. Data were evaluated using standard statistics, Mann-Whitney U tests and Chi-square tests. RESULTS Two hundred sixty-eight patients (274 lesions, median age 54 years, inter-quartile range, 50-65 years) with a PHBC (n = 46) and without a PHBC (n = 222) were included. Overall PPVs were the following: BI-RADS 2, 0% (0 of 56); BI-RADS 3, 9.1% (1 of 11); BI-RADS 4a, 16.2% (6 of 37); BI-RADS 4b, 37.5% (48 of 128); BI-RADS 4c, 47.3% (18 of 38) and BI-RADS 5, 100% (4 of 4). The PPV of BI-RADS categories was similar in patients with and without a PHBC (P = .715). Calcifications were more often malignant in patients with a PHBC older than 10 years (47.3%, 9 of 19) compared to 1-2 years (25%, 1 of 4), 2-5 years (20%, 2 of 10) and 5-10 years (0%, of 13) from the first breast cancer (P = .005). CONCLUSION PPV of mammographic calcifications is similar in women with or without PHBC when BI-RADS classification is strictly applied. A higher risk of malignancy was observed in patients with a PHBC longer than 10 years.
Collapse
Affiliation(s)
- Valeria Bertani
- Department of Oncologic Radiation Therapy and Diagnostic Imaging, Centro Di Riferimento Oncologico, Via Franco Gallini, 2, 33081 Aviano, Italy
| | - Nicole Berger
- Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland ,Institute of Radiology, Spital Lachen, Oberdorfstrasse 41, 8853 Lachen, Switzerland
| | - Matthias Eberhard
- Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland
| | - Kristina Lång
- Department of Translational Medicine, Diagnostic Radiology, Lund University, Skane University Hospital, Jan Waldenströms Gata 22, S-205 02 Malmö, Sweden
| | - Martina Urbani
- Department of Oncologic Radiation Therapy and Diagnostic Imaging, Centro Di Riferimento Oncologico, Via Franco Gallini, 2, 33081 Aviano, Italy
| | - Manuela La Grassa
- Department of Oncologic Radiation Therapy and Diagnostic Imaging, Centro Di Riferimento Oncologico, Via Franco Gallini, 2, 33081 Aviano, Italy
| | - Luca Balestreri
- Department of Oncologic Radiation Therapy and Diagnostic Imaging, Centro Di Riferimento Oncologico, Via Franco Gallini, 2, 33081 Aviano, Italy
| | - Andreas Boss
- Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland
| | - Thomas Frauenfelder
- Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland
| | - Magda Marcon
- Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland. .,Institute of Radiology, Spital Lachen, Oberdorfstrasse 41, 8853, Lachen, Switzerland.
| |
Collapse
|
4
|
BRCA 1–2 Incidence in Synchronous and Metachronous Breast Cancer: a Tertiary Center Study. Indian J Surg 2022. [DOI: 10.1007/s12262-022-03335-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
5
|
Lee JM, Ichikawa LE, Wernli KJ, Bowles E, Specht JM, Kerlikowske K, Miglioretti DL, Lowry KP, Tosteson ANA, Stout NK, Houssami N, Onega T, Buist DSM. Digital Mammography and Breast Tomosynthesis Performance in Women with a Personal History of Breast Cancer, 2007-2016. Radiology 2021; 300:290-300. [PMID: 34003059 PMCID: PMC8328154 DOI: 10.1148/radiol.2021204581] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Revised: 03/01/2021] [Accepted: 03/12/2021] [Indexed: 01/13/2023]
Abstract
Background Since 2007, digital mammography and digital breast tomosynthesis (DBT) replaced screen-film mammography. Whether these technologic advances have improved diagnostic performance has, to the knowledge of the authors, not yet been established. Purpose To evaluate the performance and outcomes of surveillance mammography (digital mammography and DBT) performed from 2007 to 2016 in women with a personal history of breast cancer and compare with data from 1996 to 2007 and the performance of digital mammography screening benchmarks. Materials and Methods In this observational cohort study, five Breast Cancer Surveillance Consortium registries provided prospectively collected mammography data linked with tumor registry and pathologic outcomes. This study identified asymptomatic women with American Joint Committee on Cancer anatomic stages 0-III primary breast cancer who underwent surveillance mammography from 2007 to 2016. The primary outcome was a second breast cancer diagnosis within 1 year of mammography. Performance measures included the recall rate, cancer detection rate, interval cancer rate, positive predictive value of biopsy recommendation, sensitivity, and specificity. Results Among 32 331 women who underwent 117 971 surveillance mammographic examinations (112 269 digital mammographic examinations and 5702 DBT examinations), the mean age at initial diagnosis was 59 years ± 12 (standard deviation). Of 1418 second breast cancers diagnosed, 998 were surveillance-detected cancers and 420 were interval cancers. The recall rate was 8.8% (10 365 of 117 971; 95% CI: 8.6%, 9.0%), the cancer detection rate was 8.5 per 1000 examinations (998 of 117 971; 95% CI: 8.0, 9.0), the interval cancer rate was 3.6 per 1000 examinations (420 of 117 971; 95% CI: 3.2, 3.9), the positive predictive value of biopsy recommendation was 31.0% (998 of 3220; 95% CI: 29.4%, 32.7%), the sensitivity was 70.4% (998 of 1418; 95% CI: 67.9%, 72.7%), and the specificity was 98.1% (114 331 of 116 553; 95% CI: 98.0%, 98.2%). Compared with previously published studies, interval cancer rate was comparable with rates from 1996 to 2007 in women with a personal history of breast cancer and was higher than the published digital mammography screening benchmarks. Conclusion In transitioning from screen-film to digital mammography and digital breast tomosynthesis, surveillance mammography performance demonstrated minimal improvement over time and remained inferior to the performance of screening mammography benchmarks. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Moy and Gao in this issue.
Collapse
Affiliation(s)
- Janie M. Lee
- From the Departments of Radiology (J.M.L., K.P.L.) and Medicine
(J.M.S.), University of Washington School of Medicine, Seattle, Wash; Seattle
Cancer Care Alliance, 1144 Eastlake Ave East, LG2-200, Seattle, WA 98109
(J.M.L., J.M.S., K.P.L.); Kaiser Permanente Washington Health Research
Institute, Seattle, Wash (L.E.I., K.J.W., E.B., D.L.M., D.S.M.B.); Department of
Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine,
Pasadena, Calif (K.J.W., D.S.M.B.); Department of Medicine, Division of General
Internal Medicine, Department of Veterans Affairs, and Department of
Epidemiology and Biostatistics, University of California, San Francisco, San
Francisco, Calif (K.K.); Division of Biostatistics, Department of Public Health
Sciences, University of California Davis School of Medicine, Davis, Calif
(D.L.M.); Dartmouth Institute for Health Policy and Clinical Practice (A.N.A.T.,
T.O.) and Norris Cotton Cancer Center (A.N.A.T.), Geisel School of Medicine,
Dartmouth College, Lebanon, NH; Department of Population Medicine, Harvard
Medical School and Harvard Pilgrim Health Care Institute, Harvard University,
Boston, Mass (N.K.S.); Faculty of Medicine and Health, Sydney School of Public
Health, University of Sydney, New South Wales, Australia (N.H.); and Huntsman
Cancer Institute, University of Utah, Salt Lake City, Utah (T.O.)
| | - Laura E. Ichikawa
- From the Departments of Radiology (J.M.L., K.P.L.) and Medicine
(J.M.S.), University of Washington School of Medicine, Seattle, Wash; Seattle
Cancer Care Alliance, 1144 Eastlake Ave East, LG2-200, Seattle, WA 98109
(J.M.L., J.M.S., K.P.L.); Kaiser Permanente Washington Health Research
Institute, Seattle, Wash (L.E.I., K.J.W., E.B., D.L.M., D.S.M.B.); Department of
Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine,
Pasadena, Calif (K.J.W., D.S.M.B.); Department of Medicine, Division of General
Internal Medicine, Department of Veterans Affairs, and Department of
Epidemiology and Biostatistics, University of California, San Francisco, San
Francisco, Calif (K.K.); Division of Biostatistics, Department of Public Health
Sciences, University of California Davis School of Medicine, Davis, Calif
(D.L.M.); Dartmouth Institute for Health Policy and Clinical Practice (A.N.A.T.,
T.O.) and Norris Cotton Cancer Center (A.N.A.T.), Geisel School of Medicine,
Dartmouth College, Lebanon, NH; Department of Population Medicine, Harvard
Medical School and Harvard Pilgrim Health Care Institute, Harvard University,
Boston, Mass (N.K.S.); Faculty of Medicine and Health, Sydney School of Public
Health, University of Sydney, New South Wales, Australia (N.H.); and Huntsman
Cancer Institute, University of Utah, Salt Lake City, Utah (T.O.)
| | - Karen J. Wernli
- From the Departments of Radiology (J.M.L., K.P.L.) and Medicine
(J.M.S.), University of Washington School of Medicine, Seattle, Wash; Seattle
Cancer Care Alliance, 1144 Eastlake Ave East, LG2-200, Seattle, WA 98109
(J.M.L., J.M.S., K.P.L.); Kaiser Permanente Washington Health Research
Institute, Seattle, Wash (L.E.I., K.J.W., E.B., D.L.M., D.S.M.B.); Department of
Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine,
Pasadena, Calif (K.J.W., D.S.M.B.); Department of Medicine, Division of General
Internal Medicine, Department of Veterans Affairs, and Department of
Epidemiology and Biostatistics, University of California, San Francisco, San
Francisco, Calif (K.K.); Division of Biostatistics, Department of Public Health
Sciences, University of California Davis School of Medicine, Davis, Calif
(D.L.M.); Dartmouth Institute for Health Policy and Clinical Practice (A.N.A.T.,
T.O.) and Norris Cotton Cancer Center (A.N.A.T.), Geisel School of Medicine,
Dartmouth College, Lebanon, NH; Department of Population Medicine, Harvard
Medical School and Harvard Pilgrim Health Care Institute, Harvard University,
Boston, Mass (N.K.S.); Faculty of Medicine and Health, Sydney School of Public
Health, University of Sydney, New South Wales, Australia (N.H.); and Huntsman
Cancer Institute, University of Utah, Salt Lake City, Utah (T.O.)
| | - Erin Bowles
- From the Departments of Radiology (J.M.L., K.P.L.) and Medicine
(J.M.S.), University of Washington School of Medicine, Seattle, Wash; Seattle
Cancer Care Alliance, 1144 Eastlake Ave East, LG2-200, Seattle, WA 98109
(J.M.L., J.M.S., K.P.L.); Kaiser Permanente Washington Health Research
Institute, Seattle, Wash (L.E.I., K.J.W., E.B., D.L.M., D.S.M.B.); Department of
Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine,
Pasadena, Calif (K.J.W., D.S.M.B.); Department of Medicine, Division of General
Internal Medicine, Department of Veterans Affairs, and Department of
Epidemiology and Biostatistics, University of California, San Francisco, San
Francisco, Calif (K.K.); Division of Biostatistics, Department of Public Health
Sciences, University of California Davis School of Medicine, Davis, Calif
(D.L.M.); Dartmouth Institute for Health Policy and Clinical Practice (A.N.A.T.,
T.O.) and Norris Cotton Cancer Center (A.N.A.T.), Geisel School of Medicine,
Dartmouth College, Lebanon, NH; Department of Population Medicine, Harvard
Medical School and Harvard Pilgrim Health Care Institute, Harvard University,
Boston, Mass (N.K.S.); Faculty of Medicine and Health, Sydney School of Public
Health, University of Sydney, New South Wales, Australia (N.H.); and Huntsman
Cancer Institute, University of Utah, Salt Lake City, Utah (T.O.)
| | - Jennifer M. Specht
- From the Departments of Radiology (J.M.L., K.P.L.) and Medicine
(J.M.S.), University of Washington School of Medicine, Seattle, Wash; Seattle
Cancer Care Alliance, 1144 Eastlake Ave East, LG2-200, Seattle, WA 98109
(J.M.L., J.M.S., K.P.L.); Kaiser Permanente Washington Health Research
Institute, Seattle, Wash (L.E.I., K.J.W., E.B., D.L.M., D.S.M.B.); Department of
Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine,
Pasadena, Calif (K.J.W., D.S.M.B.); Department of Medicine, Division of General
Internal Medicine, Department of Veterans Affairs, and Department of
Epidemiology and Biostatistics, University of California, San Francisco, San
Francisco, Calif (K.K.); Division of Biostatistics, Department of Public Health
Sciences, University of California Davis School of Medicine, Davis, Calif
(D.L.M.); Dartmouth Institute for Health Policy and Clinical Practice (A.N.A.T.,
T.O.) and Norris Cotton Cancer Center (A.N.A.T.), Geisel School of Medicine,
Dartmouth College, Lebanon, NH; Department of Population Medicine, Harvard
Medical School and Harvard Pilgrim Health Care Institute, Harvard University,
Boston, Mass (N.K.S.); Faculty of Medicine and Health, Sydney School of Public
Health, University of Sydney, New South Wales, Australia (N.H.); and Huntsman
Cancer Institute, University of Utah, Salt Lake City, Utah (T.O.)
| | - Karla Kerlikowske
- From the Departments of Radiology (J.M.L., K.P.L.) and Medicine
(J.M.S.), University of Washington School of Medicine, Seattle, Wash; Seattle
Cancer Care Alliance, 1144 Eastlake Ave East, LG2-200, Seattle, WA 98109
(J.M.L., J.M.S., K.P.L.); Kaiser Permanente Washington Health Research
Institute, Seattle, Wash (L.E.I., K.J.W., E.B., D.L.M., D.S.M.B.); Department of
Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine,
Pasadena, Calif (K.J.W., D.S.M.B.); Department of Medicine, Division of General
Internal Medicine, Department of Veterans Affairs, and Department of
Epidemiology and Biostatistics, University of California, San Francisco, San
Francisco, Calif (K.K.); Division of Biostatistics, Department of Public Health
Sciences, University of California Davis School of Medicine, Davis, Calif
(D.L.M.); Dartmouth Institute for Health Policy and Clinical Practice (A.N.A.T.,
T.O.) and Norris Cotton Cancer Center (A.N.A.T.), Geisel School of Medicine,
Dartmouth College, Lebanon, NH; Department of Population Medicine, Harvard
Medical School and Harvard Pilgrim Health Care Institute, Harvard University,
Boston, Mass (N.K.S.); Faculty of Medicine and Health, Sydney School of Public
Health, University of Sydney, New South Wales, Australia (N.H.); and Huntsman
Cancer Institute, University of Utah, Salt Lake City, Utah (T.O.)
| | - Diana L. Miglioretti
- From the Departments of Radiology (J.M.L., K.P.L.) and Medicine
(J.M.S.), University of Washington School of Medicine, Seattle, Wash; Seattle
Cancer Care Alliance, 1144 Eastlake Ave East, LG2-200, Seattle, WA 98109
(J.M.L., J.M.S., K.P.L.); Kaiser Permanente Washington Health Research
Institute, Seattle, Wash (L.E.I., K.J.W., E.B., D.L.M., D.S.M.B.); Department of
Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine,
Pasadena, Calif (K.J.W., D.S.M.B.); Department of Medicine, Division of General
Internal Medicine, Department of Veterans Affairs, and Department of
Epidemiology and Biostatistics, University of California, San Francisco, San
Francisco, Calif (K.K.); Division of Biostatistics, Department of Public Health
Sciences, University of California Davis School of Medicine, Davis, Calif
(D.L.M.); Dartmouth Institute for Health Policy and Clinical Practice (A.N.A.T.,
T.O.) and Norris Cotton Cancer Center (A.N.A.T.), Geisel School of Medicine,
Dartmouth College, Lebanon, NH; Department of Population Medicine, Harvard
Medical School and Harvard Pilgrim Health Care Institute, Harvard University,
Boston, Mass (N.K.S.); Faculty of Medicine and Health, Sydney School of Public
Health, University of Sydney, New South Wales, Australia (N.H.); and Huntsman
Cancer Institute, University of Utah, Salt Lake City, Utah (T.O.)
| | - Kathryn P. Lowry
- From the Departments of Radiology (J.M.L., K.P.L.) and Medicine
(J.M.S.), University of Washington School of Medicine, Seattle, Wash; Seattle
Cancer Care Alliance, 1144 Eastlake Ave East, LG2-200, Seattle, WA 98109
(J.M.L., J.M.S., K.P.L.); Kaiser Permanente Washington Health Research
Institute, Seattle, Wash (L.E.I., K.J.W., E.B., D.L.M., D.S.M.B.); Department of
Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine,
Pasadena, Calif (K.J.W., D.S.M.B.); Department of Medicine, Division of General
Internal Medicine, Department of Veterans Affairs, and Department of
Epidemiology and Biostatistics, University of California, San Francisco, San
Francisco, Calif (K.K.); Division of Biostatistics, Department of Public Health
Sciences, University of California Davis School of Medicine, Davis, Calif
(D.L.M.); Dartmouth Institute for Health Policy and Clinical Practice (A.N.A.T.,
T.O.) and Norris Cotton Cancer Center (A.N.A.T.), Geisel School of Medicine,
Dartmouth College, Lebanon, NH; Department of Population Medicine, Harvard
Medical School and Harvard Pilgrim Health Care Institute, Harvard University,
Boston, Mass (N.K.S.); Faculty of Medicine and Health, Sydney School of Public
Health, University of Sydney, New South Wales, Australia (N.H.); and Huntsman
Cancer Institute, University of Utah, Salt Lake City, Utah (T.O.)
| | - Anna N. A. Tosteson
- From the Departments of Radiology (J.M.L., K.P.L.) and Medicine
(J.M.S.), University of Washington School of Medicine, Seattle, Wash; Seattle
Cancer Care Alliance, 1144 Eastlake Ave East, LG2-200, Seattle, WA 98109
(J.M.L., J.M.S., K.P.L.); Kaiser Permanente Washington Health Research
Institute, Seattle, Wash (L.E.I., K.J.W., E.B., D.L.M., D.S.M.B.); Department of
Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine,
Pasadena, Calif (K.J.W., D.S.M.B.); Department of Medicine, Division of General
Internal Medicine, Department of Veterans Affairs, and Department of
Epidemiology and Biostatistics, University of California, San Francisco, San
Francisco, Calif (K.K.); Division of Biostatistics, Department of Public Health
Sciences, University of California Davis School of Medicine, Davis, Calif
(D.L.M.); Dartmouth Institute for Health Policy and Clinical Practice (A.N.A.T.,
T.O.) and Norris Cotton Cancer Center (A.N.A.T.), Geisel School of Medicine,
Dartmouth College, Lebanon, NH; Department of Population Medicine, Harvard
Medical School and Harvard Pilgrim Health Care Institute, Harvard University,
Boston, Mass (N.K.S.); Faculty of Medicine and Health, Sydney School of Public
Health, University of Sydney, New South Wales, Australia (N.H.); and Huntsman
Cancer Institute, University of Utah, Salt Lake City, Utah (T.O.)
| | - Natasha K. Stout
- From the Departments of Radiology (J.M.L., K.P.L.) and Medicine
(J.M.S.), University of Washington School of Medicine, Seattle, Wash; Seattle
Cancer Care Alliance, 1144 Eastlake Ave East, LG2-200, Seattle, WA 98109
(J.M.L., J.M.S., K.P.L.); Kaiser Permanente Washington Health Research
Institute, Seattle, Wash (L.E.I., K.J.W., E.B., D.L.M., D.S.M.B.); Department of
Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine,
Pasadena, Calif (K.J.W., D.S.M.B.); Department of Medicine, Division of General
Internal Medicine, Department of Veterans Affairs, and Department of
Epidemiology and Biostatistics, University of California, San Francisco, San
Francisco, Calif (K.K.); Division of Biostatistics, Department of Public Health
Sciences, University of California Davis School of Medicine, Davis, Calif
(D.L.M.); Dartmouth Institute for Health Policy and Clinical Practice (A.N.A.T.,
T.O.) and Norris Cotton Cancer Center (A.N.A.T.), Geisel School of Medicine,
Dartmouth College, Lebanon, NH; Department of Population Medicine, Harvard
Medical School and Harvard Pilgrim Health Care Institute, Harvard University,
Boston, Mass (N.K.S.); Faculty of Medicine and Health, Sydney School of Public
Health, University of Sydney, New South Wales, Australia (N.H.); and Huntsman
Cancer Institute, University of Utah, Salt Lake City, Utah (T.O.)
| | - Nehmat Houssami
- From the Departments of Radiology (J.M.L., K.P.L.) and Medicine
(J.M.S.), University of Washington School of Medicine, Seattle, Wash; Seattle
Cancer Care Alliance, 1144 Eastlake Ave East, LG2-200, Seattle, WA 98109
(J.M.L., J.M.S., K.P.L.); Kaiser Permanente Washington Health Research
Institute, Seattle, Wash (L.E.I., K.J.W., E.B., D.L.M., D.S.M.B.); Department of
Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine,
Pasadena, Calif (K.J.W., D.S.M.B.); Department of Medicine, Division of General
Internal Medicine, Department of Veterans Affairs, and Department of
Epidemiology and Biostatistics, University of California, San Francisco, San
Francisco, Calif (K.K.); Division of Biostatistics, Department of Public Health
Sciences, University of California Davis School of Medicine, Davis, Calif
(D.L.M.); Dartmouth Institute for Health Policy and Clinical Practice (A.N.A.T.,
T.O.) and Norris Cotton Cancer Center (A.N.A.T.), Geisel School of Medicine,
Dartmouth College, Lebanon, NH; Department of Population Medicine, Harvard
Medical School and Harvard Pilgrim Health Care Institute, Harvard University,
Boston, Mass (N.K.S.); Faculty of Medicine and Health, Sydney School of Public
Health, University of Sydney, New South Wales, Australia (N.H.); and Huntsman
Cancer Institute, University of Utah, Salt Lake City, Utah (T.O.)
| | - Tracy Onega
- From the Departments of Radiology (J.M.L., K.P.L.) and Medicine
(J.M.S.), University of Washington School of Medicine, Seattle, Wash; Seattle
Cancer Care Alliance, 1144 Eastlake Ave East, LG2-200, Seattle, WA 98109
(J.M.L., J.M.S., K.P.L.); Kaiser Permanente Washington Health Research
Institute, Seattle, Wash (L.E.I., K.J.W., E.B., D.L.M., D.S.M.B.); Department of
Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine,
Pasadena, Calif (K.J.W., D.S.M.B.); Department of Medicine, Division of General
Internal Medicine, Department of Veterans Affairs, and Department of
Epidemiology and Biostatistics, University of California, San Francisco, San
Francisco, Calif (K.K.); Division of Biostatistics, Department of Public Health
Sciences, University of California Davis School of Medicine, Davis, Calif
(D.L.M.); Dartmouth Institute for Health Policy and Clinical Practice (A.N.A.T.,
T.O.) and Norris Cotton Cancer Center (A.N.A.T.), Geisel School of Medicine,
Dartmouth College, Lebanon, NH; Department of Population Medicine, Harvard
Medical School and Harvard Pilgrim Health Care Institute, Harvard University,
Boston, Mass (N.K.S.); Faculty of Medicine and Health, Sydney School of Public
Health, University of Sydney, New South Wales, Australia (N.H.); and Huntsman
Cancer Institute, University of Utah, Salt Lake City, Utah (T.O.)
| | - Diana S. M. Buist
- From the Departments of Radiology (J.M.L., K.P.L.) and Medicine
(J.M.S.), University of Washington School of Medicine, Seattle, Wash; Seattle
Cancer Care Alliance, 1144 Eastlake Ave East, LG2-200, Seattle, WA 98109
(J.M.L., J.M.S., K.P.L.); Kaiser Permanente Washington Health Research
Institute, Seattle, Wash (L.E.I., K.J.W., E.B., D.L.M., D.S.M.B.); Department of
Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine,
Pasadena, Calif (K.J.W., D.S.M.B.); Department of Medicine, Division of General
Internal Medicine, Department of Veterans Affairs, and Department of
Epidemiology and Biostatistics, University of California, San Francisco, San
Francisco, Calif (K.K.); Division of Biostatistics, Department of Public Health
Sciences, University of California Davis School of Medicine, Davis, Calif
(D.L.M.); Dartmouth Institute for Health Policy and Clinical Practice (A.N.A.T.,
T.O.) and Norris Cotton Cancer Center (A.N.A.T.), Geisel School of Medicine,
Dartmouth College, Lebanon, NH; Department of Population Medicine, Harvard
Medical School and Harvard Pilgrim Health Care Institute, Harvard University,
Boston, Mass (N.K.S.); Faculty of Medicine and Health, Sydney School of Public
Health, University of Sydney, New South Wales, Australia (N.H.); and Huntsman
Cancer Institute, University of Utah, Salt Lake City, Utah (T.O.)
| |
Collapse
|
6
|
Bloom JA, Sekigami Y, Young R, Macera L, Russell CA, Cao Y, Buchsbaum RJ, Naber SP, Chatterjee A. Discordance in Oncotype DX Breast Recurrence Score ® Results for Bilateral Breast Cancer. Ann Surg Oncol 2021; 28:8711-8716. [PMID: 34241750 DOI: 10.1245/s10434-021-10387-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Accepted: 06/17/2021] [Indexed: 11/18/2022]
Abstract
BACKGROUND The Oncotype DX Breast Recurrence Score® assay is a clinically useful tool to determine the benefit of chemotherapy in the treatment of early-stage, hormone-receptor-positive breast cancer. Bilateral breast cancer (BBC) is found in ~ 5% of patients with breast cancer, and data regarding discordance of Oncotype DX results between BBC defined by current TAILORx subgroups are limited. Our goals are to study the rate of Oncotype DX discordance between BBC and investigate whether such differences can affect chemotherapy treatment discussions. METHODS Patients with BBC were identified in US samples submitted to Genomic Health for 21-gene testing between January 2019 and July 2020. The risk categories were defined as 0-25 and 26-100 as well as 0-17, 18-30, and 31-100 for all patients. Subgroup analysis was also performed for node-negative women age ≤ 50 years with Recurrence Score results of 0-15, 16-20, 21-25, and 26-100. RESULTS 944 BBC patients with known nodal status (702 node negative, 242 node positive) were identified and included. Among node-negative patients aged > 50 years, the rate of discordance in Recurrence Score by group (0-25 and 26-100) was 4.2% (n = 598). For node-negative patients aged ≤ 50 years, the risk group was discordant in < 3% when considering the risk grouping of 0-25 and 26-100. However, upon subgroup analysis based on TAILORx analysis, the rate of discordance was 48.1% in these younger patients (n = 104). CONCLUSIONS This study shows that a clinically relevant rate of discordance in Oncotype DX results in patients with BBC may impact medical decision-making regarding chemotherapy.
Collapse
Affiliation(s)
- Joshua A Bloom
- Department of Surgery, Tufts Medical Center, Boston, MA, USA.
| | - Yurie Sekigami
- Department of Surgery, Tufts Medical Center, Boston, MA, USA
| | | | - Lisa Macera
- Exact Sciences Corporation, Redwood City, CA, USA
| | | | - Yu Cao
- Division of Hematology/Oncology, Department of Medicine, Tufts Medical Center, Boston, MA, USA
| | - Rachel J Buchsbaum
- Division of Hematology/Oncology, Department of Medicine, Tufts Medical Center, Boston, MA, USA
| | - Stephen P Naber
- Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, MA, USA
| | | |
Collapse
|
7
|
Fanale D, Incorvaia L, Filorizzo C, Bono M, Fiorino A, Calò V, Brando C, Corsini LR, Barraco N, Badalamenti G, Russo A, Bazan V. Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2. Cancers (Basel) 2020; 12:E2415. [PMID: 32854451 PMCID: PMC7564956 DOI: 10.3390/cancers12092415] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Revised: 08/23/2020] [Accepted: 08/24/2020] [Indexed: 12/24/2022] Open
Abstract
Patients with unilateral breast cancer (UBC) have an increased risk of developing bilateral breast cancer (BBC). The annual risk of contralateral BC is about 0.5%, but increases by up to 3% in BRCA1 or BRCA2 pathogenic variant (PV) carriers. Our study was aimed to evaluate whether all BBC patients should be offered multi-gene panel testing, regardless their cancer family history and age at diagnosis. We retrospectively collected all clinical information of 139 BBC patients genetically tested for germline PVs in different cancer susceptibility genes by NGS-based multi-gene panel testing. Our investigation revealed that 52 (37.4%) out of 139 BBC patients harbored germline PVs in high- and intermediate-penetrance breast cancer (BC) susceptibility genes including BRCA1, BRCA2, PTEN, PALB2, CHEK2, ATM, RAD51C. Nineteen out of 53 positively tested patients harbored a PV in a known BC susceptibility gene (no-BRCA). Interestingly, in the absence of an analysis performed via multi-gene panel, a significant proportion (14.4%) of PVs would have been lost. Therefore, offering a NGS-based multi-gene panel testing to all BBC patients may significantly increase the detection rates of germline PVs in other cancer susceptibility genes beyond BRCA1/2, avoiding underestimation of the number of individuals affected by a hereditary tumor syndrome.
Collapse
Affiliation(s)
- Daniele Fanale
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy; (D.F.); (C.F.); (M.B.); (A.F.); (V.C.); (C.B.); (L.R.C.); (N.B.); (G.B.)
| | - Lorena Incorvaia
- Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy; (L.I.); (V.B.)
| | - Clarissa Filorizzo
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy; (D.F.); (C.F.); (M.B.); (A.F.); (V.C.); (C.B.); (L.R.C.); (N.B.); (G.B.)
| | - Marco Bono
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy; (D.F.); (C.F.); (M.B.); (A.F.); (V.C.); (C.B.); (L.R.C.); (N.B.); (G.B.)
| | - Alessia Fiorino
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy; (D.F.); (C.F.); (M.B.); (A.F.); (V.C.); (C.B.); (L.R.C.); (N.B.); (G.B.)
| | - Valentina Calò
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy; (D.F.); (C.F.); (M.B.); (A.F.); (V.C.); (C.B.); (L.R.C.); (N.B.); (G.B.)
| | - Chiara Brando
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy; (D.F.); (C.F.); (M.B.); (A.F.); (V.C.); (C.B.); (L.R.C.); (N.B.); (G.B.)
| | - Lidia Rita Corsini
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy; (D.F.); (C.F.); (M.B.); (A.F.); (V.C.); (C.B.); (L.R.C.); (N.B.); (G.B.)
| | - Nadia Barraco
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy; (D.F.); (C.F.); (M.B.); (A.F.); (V.C.); (C.B.); (L.R.C.); (N.B.); (G.B.)
| | - Giuseppe Badalamenti
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy; (D.F.); (C.F.); (M.B.); (A.F.); (V.C.); (C.B.); (L.R.C.); (N.B.); (G.B.)
| | - Antonio Russo
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy; (D.F.); (C.F.); (M.B.); (A.F.); (V.C.); (C.B.); (L.R.C.); (N.B.); (G.B.)
| | - Viviana Bazan
- Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy; (L.I.); (V.B.)
| |
Collapse
|
8
|
Njor SH, Vejborg I, Larsen MB. Breast cancer survivors' risk of interval cancers and false positive results in organized mammography screening. Cancer Med 2020; 9:6042-6050. [PMID: 32608178 PMCID: PMC7433834 DOI: 10.1002/cam4.3182] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2020] [Revised: 05/05/2020] [Accepted: 05/07/2020] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Breast cancer survivors are increasing followed for new breast cancers / recurrences by mammography screening only. We aimed at assessing how often breast cancer survivors get a false positive or false negative result at mammography screening. METHODS All mammography screenings performed between 2007 and 2017 in the Danish national mammography screening programme were included. Screenings in women with a breast cancer diagnosis prior to invitation were included in the "breast cancer survivors" group, while remaining screenings were included in the "no previous breast cancer" group. We compared the proportion of false positive screenings and the proportion of breast cancers detected at screening among breast cancer survivors and women without previous breast cancer. The analyses were further stratified according to whether the women had a diagnostic breast imaging in the 21 months prior to the screening. RESULTS At initial screenings, breast cancer survivors had a significant lower false positive risk than other women, while the risk was similar at subsequent screenings. Breast cancer survivors had a significant lower proportion of breast cancers detected at screening compared to other women. This was true both for women who had a diagnostic breast imaging in the 21 months prior to screening and those who did not. CONCLUSION This study shows that breast cancers survivors have a smaller amount of their new breast cancers detected at mammography screening, when compare to the amount of new breast cancers detected at mammography screening among women without previous breast cancer. The lower sensitivity does not seem to be due to different behavior among breast cancer survivors.
Collapse
Affiliation(s)
- Sisse Helle Njor
- Department of Public Health Programmes, Regional Hospital Randers, Randers, Denmark.,Department of Clinical Medicine, Aarhus University, aarhus, Denmark
| | - Ilse Vejborg
- Department of Radiology, Copenhagen University Hospital, Rigshospitalet, Denmark
| | - Mette Bach Larsen
- Department of Public Health Programmes, Regional Hospital Randers, Randers, Denmark
| |
Collapse
|
9
|
Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review and meta-analysis. Breast Cancer Res Treat 2020; 181:255-268. [PMID: 32303988 DOI: 10.1007/s10549-020-05637-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2019] [Accepted: 04/08/2020] [Indexed: 10/24/2022]
Abstract
PURPOSE Women with personal history of breast cancer (PHBC) are currently recommended to receive annual mammography for surveillance of breast cancer recurrence or new primary. However, given issues in accuracy with mammography, there is a need for evolving evidence-based surveillance recommendations with supplemental imaging. In this systematic review, we compiled and compared existing studies that describe the test performance of surveillance breast MRI among women with PHBC. METHODS We searched PubMed and EMBASE using MeSH terms for studies (2000-2019) that described the diagnostic characteristics of breast MRI in women with PHBC. Search results were reviewed and included based on PICOTS criteria; quality of included articles was assessed using QUADAS-2. Meta-analysis of single proportions was conducted for diagnostic characteristics of breast MRI, including tests of heterogeneity. RESULTS Our review included 11 articles in which unique cohorts were studied, comprised of a total of 8338 women with PHBC and 12,335 breast MRI done for the purpose of surveillance. We predict intervals (PI) for cancer detection rate per 1000 examinations (PI 9-15; I2 = 10%), recall rate (PI 5-31%; I2 = 97%), sensitivity (PI 58-95%; I2 = 47%), specificity (PI 76-97%; I2 = 97%), and PPV3 (PI 16-40%; I2 = 44%). CONCLUSIONS Studies addressing performance of breast MRI are variable and limited in population-based studies. The summary of evidence to date is insufficient to recommend for or against use of breast MRI for surveillance among women with PHBC.
Collapse
|
10
|
Giardiello D, Steyerberg EW, Hauptmann M, Adank MA, Akdeniz D, Blomqvist C, Bojesen SE, Bolla MK, Brinkhuis M, Chang-Claude J, Czene K, Devilee P, Dunning AM, Easton DF, Eccles DM, Fasching PA, Figueroa J, Flyger H, García-Closas M, Haeberle L, Haiman CA, Hall P, Hamann U, Hopper JL, Jager A, Jakubowska A, Jung A, Keeman R, Kramer I, Lambrechts D, Le Marchand L, Lindblom A, Lubiński J, Manoochehri M, Mariani L, Nevanlinna H, Oldenburg HSA, Pelders S, Pharoah PDP, Shah M, Siesling S, Smit VTHBM, Southey MC, Tapper WJ, Tollenaar RAEM, van den Broek AJ, van Deurzen CHM, van Leeuwen FE, van Ongeval C, Van't Veer LJ, Wang Q, Wendt C, Westenend PJ, Hooning MJ, Schmidt MK. Prediction and clinical utility of a contralateral breast cancer risk model. Breast Cancer Res 2019; 21:144. [PMID: 31847907 PMCID: PMC6918633 DOI: 10.1186/s13058-019-1221-1] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2019] [Accepted: 10/29/2019] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND Breast cancer survivors are at risk for contralateral breast cancer (CBC), with the consequent burden of further treatment and potentially less favorable prognosis. We aimed to develop and validate a CBC risk prediction model and evaluate its applicability for clinical decision-making. METHODS We included data of 132,756 invasive non-metastatic breast cancer patients from 20 studies with 4682 CBC events and a median follow-up of 8.8 years. We developed a multivariable Fine and Gray prediction model (PredictCBC-1A) including patient, primary tumor, and treatment characteristics and BRCA1/2 germline mutation status, accounting for the competing risks of death and distant metastasis. We also developed a model without BRCA1/2 mutation status (PredictCBC-1B) since this information was available for only 6% of patients and is routinely unavailable in the general breast cancer population. Prediction performance was evaluated using calibration and discrimination, calculated by a time-dependent area under the curve (AUC) at 5 and 10 years after diagnosis of primary breast cancer, and an internal-external cross-validation procedure. Decision curve analysis was performed to evaluate the net benefit of the model to quantify clinical utility. RESULTS In the multivariable model, BRCA1/2 germline mutation status, family history, and systemic adjuvant treatment showed the strongest associations with CBC risk. The AUC of PredictCBC-1A was 0.63 (95% prediction interval (PI) at 5 years, 0.52-0.74; at 10 years, 0.53-0.72). Calibration-in-the-large was -0.13 (95% PI: -1.62-1.37), and the calibration slope was 0.90 (95% PI: 0.73-1.08). The AUC of Predict-1B at 10 years was 0.59 (95% PI: 0.52-0.66); calibration was slightly lower. Decision curve analysis for preventive contralateral mastectomy showed potential clinical utility of PredictCBC-1A between thresholds of 4-10% 10-year CBC risk for BRCA1/2 mutation carriers and non-carriers. CONCLUSIONS We developed a reasonably calibrated model to predict the risk of CBC in women of European-descent; however, prediction accuracy was moderate. Our model shows potential for improved risk counseling, but decision-making regarding contralateral preventive mastectomy, especially in the general breast cancer population where limited information of the mutation status in BRCA1/2 is available, remains challenging.
Collapse
Affiliation(s)
- Daniele Giardiello
- Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands
| | - Ewout W Steyerberg
- Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands
- Department of Public Health, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - Michael Hauptmann
- Institute of Biometry and Registry Research, Brandenburg Medical School, Neuruppin, Germany
- Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Muriel A Adank
- The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Family Cancer Clinic, Amsterdam, The Netherlands
| | - Delal Akdeniz
- Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - Carl Blomqvist
- Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
- Department of Oncology, Örebro University Hospital, Örebro, Sweden
| | - Stig E Bojesen
- Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
- Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Manjeet K Bolla
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Mariël Brinkhuis
- East-Netherlands, Laboratory for Pathology, Hengelo, The Netherlands
| | - Jenny Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Kamila Czene
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Peter Devilee
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
- Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - Alison M Dunning
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Douglas F Easton
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Diana M Eccles
- Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK
| | - Peter A Fasching
- Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA
- Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
| | - Jonine Figueroa
- Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh, UK
- Cancer Research UK Edinburgh Centre, Edinburgh, UK
- Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Henrik Flyger
- Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
| | - Montserrat García-Closas
- Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
| | - Lothar Haeberle
- Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
| | - Christopher A Haiman
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Per Hall
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
- Department of Oncology, Södersjukhuset, Stockholm, Sweden
| | - Ute Hamann
- Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - John L Hopper
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia
| | - Agnes Jager
- Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - Anna Jakubowska
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
- Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland
| | - Audrey Jung
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Renske Keeman
- Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Iris Kramer
- Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Diether Lambrechts
- VIB Center for Cancer Biology, VIB, Leuven, Belgium
- Laboratory for Translational Genetics, Department of Human Genetics, University of Leuven, Leuven, Belgium
| | - Loic Le Marchand
- University of Hawaii Cancer Center, Epidemiology Program, Honolulu, HI, USA
| | - Annika Lindblom
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
- Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden
| | - Jan Lubiński
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Mehdi Manoochehri
- Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Luigi Mariani
- Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Heli Nevanlinna
- Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
| | - Hester S A Oldenburg
- Department of Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Saskia Pelders
- Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - Paul D P Pharoah
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Mitul Shah
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Sabine Siesling
- Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands
| | - Vincent T H B M Smit
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
| | - Melissa C Southey
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
- Department of Clinical Pathology, The University of Melbourne, Melbourne, Victoria, Australia
| | | | - Rob A E M Tollenaar
- Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
| | - Alexandra J van den Broek
- Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | | | - Flora E van Leeuwen
- Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands
| | - Chantal van Ongeval
- Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
| | - Laura J Van't Veer
- Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Qin Wang
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Camilla Wendt
- Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden
| | | | - Maartje J Hooning
- Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - Marjanka K Schmidt
- Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
- Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
| |
Collapse
|
11
|
Surveillance Magnetic Resonance Imaging in Detecting the Second Breast Cancer in Women With a Personal History of Breast Cancer. J Comput Assist Tomogr 2019; 43:937-942. [PMID: 31738203 DOI: 10.1097/rct.0000000000000931] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE The objective of this study was to evaluate the diagnostic performance of magnetic resonance imaging (MRI) in detecting the secondary breast cancer among women with a personal history of the lesion. MATERIALS AND METHODS We retrospectively reviewed breast MRI examinations performed between 2007 and 2011. A total of 798 women with a history of breast cancer were included in the study. Cancer detection rate, positive predictive value (PPV), recall rate, sensitivity, and specificity were assed. Cancer detection rate was stratified by interval after surgery of the primary breast cancer. Also, we derived 1 comparison group from the women for comparing the performance of x-ray mammography, ultrasound, and MRI in detecting the second breast cancer. RESULTS Of the 798 patients, 47 of the 49 secondary breast carcinomas were detected by MRI. The sensitivity and specificity of MRI in detecting the secondary lesions were 95.9% and 96.3%, respectively. The recall rate was 9.5%, and the PPV was 61.8%. Cancer detection rate of MRI examinations performed at more than 36 months after initial surgery was significantly higher than that at 36 months or less after initial surgery (13.7% vs 3.6, P < 0.001). In comparison group, the sensitivity and specificity of MRI, mammography, and ultrasound were 96.7% and 96.1%, 48.4% and 93.9%, and 77.4% and 96.1%, respectively. CONCLUSIONS Surveillance MRI for women with a personal history of breast cancer has high sensitivity in finding the secondary malignancies with a reasonable recall rate and PPV.
Collapse
|
12
|
Shen K, Yao L, Wei J, Luo Z, Yu W, Zhai H, Wang J, Chen L, Fu D. Worse characteristics can predict survival effectively in bilateral primary breast cancer: A competing risk nomogram using the SEER database. Cancer Med 2019; 8:7890-7902. [PMID: 31663683 PMCID: PMC6912037 DOI: 10.1002/cam4.2662] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2019] [Revised: 10/10/2019] [Accepted: 10/14/2019] [Indexed: 12/18/2022] Open
Abstract
Objective There is limited information from population‐based cancer registries regarding prognostic features of bilateral primary breast cancer (BPBC). Methods Female patients diagnosed with BPBC between 2004 and 2014 were randomly divided into training (n = 7740) and validation (n = 2579) cohorts from the Surveillance, Epidemiology, and End Results Database. We proposed five various models. Multivariate Cox hazard regression and competing risk analysis were to explore prognosis factors in training cohort. Competing risk nomograms were constructed to combine significant prognostic factors to predict the 3‐year and the 5‐year survival of patients with BPBC. At last, in the validation cohort, the new score performance was evaluated with respect to the area under curve, concordance index, net reclassification index and calibration curve. Results We found out that age, interval time, lymph nodes invasion, tumor size, tumor grade and estrogen receptor status were independent prognostic factors in both multivariate Cox hazard regression analysis and competing risk analysis. Concordance index in the model of the worse characteristics was 0.816 (95% CI: 0.791‐0.840), of the bilateral tumors was 0.819 (95% CI: 0.793‐0.844), of the worse tumor was 0.807 (0.782‐0.832), of the first tumor was 0.744 (0.728‐0.763) and of the second tumor was 0.778 (0.762‐0.794). Net reclassification index of the 3‐year and the 5‐year between them was 2.7% and −1.0%. The calibration curves showed high concordance between the nomogram prediction and actual observation. Conclusion The prognosis of BPBC depended on bilateral tumors. The competing risk nomogram of the model of the worse characteristics may help clinicians predict survival simply and effectively. Metachronous bilateral breast cancer presented poorer survival than synchronous bilateral breast cancer.
Collapse
Affiliation(s)
- Kaiwen Shen
- Yangzhou University Medical Academy, Yangzhou, Jiangsu, China
| | - Longdi Yao
- The Second Clinical College of Dalian Medical University, Dalian, Liaoning, China
| | - Jinli Wei
- Department of Thyroid and Breast Surgery, Yangzhou University Affiliated Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China
| | - Zhou Luo
- Department of Thyroid and Breast Surgery, Yangzhou University Affiliated Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China
| | - Wang Yu
- Department of Thyroid and Breast Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Huamin Zhai
- Yangzhou University Medical Academy, Yangzhou, Jiangsu, China
| | - Jianwen Wang
- Yangzhou University Medical Academy, Yangzhou, Jiangsu, China
| | - Luhong Chen
- Yangzhou University Medical Academy, Yangzhou, Jiangsu, China
| | - Deyuan Fu
- Yangzhou University Medical Academy, Yangzhou, Jiangsu, China.,Department of Thyroid and Breast Surgery, Yangzhou University Affiliated Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China
| |
Collapse
|
13
|
Wernli KJ, Ichikawa L, Kerlikowske K, Buist DSM, Brandzel SD, Bush M, Johnson D, Henderson LM, Nekhlyudov L, Onega T, Sprague BL, Lee JM, Lehman CD, Miglioretti DL. Surveillance Breast MRI and Mammography: Comparison in Women with a Personal History of Breast Cancer. Radiology 2019; 292:311-318. [PMID: 31161975 PMCID: PMC6694722 DOI: 10.1148/radiol.2019182475] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Revised: 04/05/2019] [Accepted: 04/12/2019] [Indexed: 01/24/2023]
Abstract
Background There is lack of consensus regarding the use of breast MRI for routine surveillance for second breast cancer events in women with a personal history of breast cancer. Purpose To compare performance of surveillance mammography with breast MRI. Materials and Methods This observational cohort study used prospectively collected data and included 13 266 women age 18 years and older (mean age, 60 years ± 13) with stage 0-III breast cancer who underwent 33 938 mammographic examinations and 2506 breast MRI examinations from 2005 to 2012 in the Breast Cancer Surveillance Consortium. Women were categorized into two groups: mammography alone (n = 11 745) or breast MRI (n = 1521). Performance measures were calculated by using end-of-day assessment and occurrence of second breast cancer events within 1 year of imaging. Logistic regression was used to compare performance for breast MRI versus mammography alone, adjusting for women, examination, and primary breast cancer characteristics. Analysis was conducted on a per-examination basis. Results Breast MRI was associated with younger age at diagnosis, chemotherapy, and higher education and income. Raw performance measures for breast MRI versus mammography were as follows, respectively: cancer detection rates, 10.8 (95% confidence interval [CI]: 6.7, 14.8) versus 8.2 (95% CI: 7.3, 9.2) per 1000 examinations; sensitivity, 61.4% (27 of 44; 95% CI: 46.5%, 76.2%) versus 70.3% (279 of 397; 95% CI: 65.8%, 74.8%); and biopsy rate, 10.1% (253 of 2506; 95% CI: 8.9%, 11.3%) versus 4.0% (1343 of 33 938; 95% CI: 3.7%, 4.2%). In multivariable models, breast MRI was associated with higher biopsy rate (odds ratio [OR], 2.2; 95% CI: 1.9, 2.7; P < .001) and cancer detection rate (OR, 1.7; 95% CI: 1.1, 2.7; P = .03) than mammography alone. However, there were no differences in sensitivity (OR, 1.1; 95% CI: 0.4, 2.9; P = .84) or interval cancer rate (OR, 1.1; 95% CI: 0.6, 2.2; P = .70). Conclusion Comparison of the performance of surveillance breast MRI with mammography must account for patient characteristics. Whereas breast MRI leads to higher biopsy and cancer detection rates, there were no significant differences in sensitivity or interval cancers compared with mammography. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Newell in this issue.
Collapse
Affiliation(s)
- Karen J. Wernli
- From the Kaiser Permanente Washington Health Research Institute, 1730
Minor Ave, Suite 1600, Seattle, WA 98101 (K.J.W., L.I., D.S.M.B., S.D.B., M.B.,
D.J., D.L.M.); Departments of Medicine and Epidemiology and Biostatistics,
General Internal Medicine Section, Department of Veterans Affairs, University of
California, San Francisco, San Francisco, Calif (K.K.); Department of Radiology,
University of North Carolina, Chapel Hill, NC (L.M.H.); Department of Medicine,
Brigham and Women’s Hospital, Boston, Mass (L.N.); Department of
Biomedical Data Science, Norris Cotton Cancer Center, Dartmouth Medical School,
Hanover, NH (T.O.); Departments of Surgery and Radiology, University of Vermont,
Burlington, Vt (B.L.S.); Department of Radiology, University of Washington,
Seattle Cancer Care Alliance Seattle, Wash (J.M.L.); Department of Radiology,
Massachusetts General Hospital, Boston, Mass (C.D.L.); Department of Public
Health Sciences, University of California, Davis, Davis, Calif (D.L.M.)
| | - Laura Ichikawa
- From the Kaiser Permanente Washington Health Research Institute, 1730
Minor Ave, Suite 1600, Seattle, WA 98101 (K.J.W., L.I., D.S.M.B., S.D.B., M.B.,
D.J., D.L.M.); Departments of Medicine and Epidemiology and Biostatistics,
General Internal Medicine Section, Department of Veterans Affairs, University of
California, San Francisco, San Francisco, Calif (K.K.); Department of Radiology,
University of North Carolina, Chapel Hill, NC (L.M.H.); Department of Medicine,
Brigham and Women’s Hospital, Boston, Mass (L.N.); Department of
Biomedical Data Science, Norris Cotton Cancer Center, Dartmouth Medical School,
Hanover, NH (T.O.); Departments of Surgery and Radiology, University of Vermont,
Burlington, Vt (B.L.S.); Department of Radiology, University of Washington,
Seattle Cancer Care Alliance Seattle, Wash (J.M.L.); Department of Radiology,
Massachusetts General Hospital, Boston, Mass (C.D.L.); Department of Public
Health Sciences, University of California, Davis, Davis, Calif (D.L.M.)
| | - Karla Kerlikowske
- From the Kaiser Permanente Washington Health Research Institute, 1730
Minor Ave, Suite 1600, Seattle, WA 98101 (K.J.W., L.I., D.S.M.B., S.D.B., M.B.,
D.J., D.L.M.); Departments of Medicine and Epidemiology and Biostatistics,
General Internal Medicine Section, Department of Veterans Affairs, University of
California, San Francisco, San Francisco, Calif (K.K.); Department of Radiology,
University of North Carolina, Chapel Hill, NC (L.M.H.); Department of Medicine,
Brigham and Women’s Hospital, Boston, Mass (L.N.); Department of
Biomedical Data Science, Norris Cotton Cancer Center, Dartmouth Medical School,
Hanover, NH (T.O.); Departments of Surgery and Radiology, University of Vermont,
Burlington, Vt (B.L.S.); Department of Radiology, University of Washington,
Seattle Cancer Care Alliance Seattle, Wash (J.M.L.); Department of Radiology,
Massachusetts General Hospital, Boston, Mass (C.D.L.); Department of Public
Health Sciences, University of California, Davis, Davis, Calif (D.L.M.)
| | - Diana S. M. Buist
- From the Kaiser Permanente Washington Health Research Institute, 1730
Minor Ave, Suite 1600, Seattle, WA 98101 (K.J.W., L.I., D.S.M.B., S.D.B., M.B.,
D.J., D.L.M.); Departments of Medicine and Epidemiology and Biostatistics,
General Internal Medicine Section, Department of Veterans Affairs, University of
California, San Francisco, San Francisco, Calif (K.K.); Department of Radiology,
University of North Carolina, Chapel Hill, NC (L.M.H.); Department of Medicine,
Brigham and Women’s Hospital, Boston, Mass (L.N.); Department of
Biomedical Data Science, Norris Cotton Cancer Center, Dartmouth Medical School,
Hanover, NH (T.O.); Departments of Surgery and Radiology, University of Vermont,
Burlington, Vt (B.L.S.); Department of Radiology, University of Washington,
Seattle Cancer Care Alliance Seattle, Wash (J.M.L.); Department of Radiology,
Massachusetts General Hospital, Boston, Mass (C.D.L.); Department of Public
Health Sciences, University of California, Davis, Davis, Calif (D.L.M.)
| | - Susan D. Brandzel
- From the Kaiser Permanente Washington Health Research Institute, 1730
Minor Ave, Suite 1600, Seattle, WA 98101 (K.J.W., L.I., D.S.M.B., S.D.B., M.B.,
D.J., D.L.M.); Departments of Medicine and Epidemiology and Biostatistics,
General Internal Medicine Section, Department of Veterans Affairs, University of
California, San Francisco, San Francisco, Calif (K.K.); Department of Radiology,
University of North Carolina, Chapel Hill, NC (L.M.H.); Department of Medicine,
Brigham and Women’s Hospital, Boston, Mass (L.N.); Department of
Biomedical Data Science, Norris Cotton Cancer Center, Dartmouth Medical School,
Hanover, NH (T.O.); Departments of Surgery and Radiology, University of Vermont,
Burlington, Vt (B.L.S.); Department of Radiology, University of Washington,
Seattle Cancer Care Alliance Seattle, Wash (J.M.L.); Department of Radiology,
Massachusetts General Hospital, Boston, Mass (C.D.L.); Department of Public
Health Sciences, University of California, Davis, Davis, Calif (D.L.M.)
| | - Mary Bush
- From the Kaiser Permanente Washington Health Research Institute, 1730
Minor Ave, Suite 1600, Seattle, WA 98101 (K.J.W., L.I., D.S.M.B., S.D.B., M.B.,
D.J., D.L.M.); Departments of Medicine and Epidemiology and Biostatistics,
General Internal Medicine Section, Department of Veterans Affairs, University of
California, San Francisco, San Francisco, Calif (K.K.); Department of Radiology,
University of North Carolina, Chapel Hill, NC (L.M.H.); Department of Medicine,
Brigham and Women’s Hospital, Boston, Mass (L.N.); Department of
Biomedical Data Science, Norris Cotton Cancer Center, Dartmouth Medical School,
Hanover, NH (T.O.); Departments of Surgery and Radiology, University of Vermont,
Burlington, Vt (B.L.S.); Department of Radiology, University of Washington,
Seattle Cancer Care Alliance Seattle, Wash (J.M.L.); Department of Radiology,
Massachusetts General Hospital, Boston, Mass (C.D.L.); Department of Public
Health Sciences, University of California, Davis, Davis, Calif (D.L.M.)
| | - Dianne Johnson
- From the Kaiser Permanente Washington Health Research Institute, 1730
Minor Ave, Suite 1600, Seattle, WA 98101 (K.J.W., L.I., D.S.M.B., S.D.B., M.B.,
D.J., D.L.M.); Departments of Medicine and Epidemiology and Biostatistics,
General Internal Medicine Section, Department of Veterans Affairs, University of
California, San Francisco, San Francisco, Calif (K.K.); Department of Radiology,
University of North Carolina, Chapel Hill, NC (L.M.H.); Department of Medicine,
Brigham and Women’s Hospital, Boston, Mass (L.N.); Department of
Biomedical Data Science, Norris Cotton Cancer Center, Dartmouth Medical School,
Hanover, NH (T.O.); Departments of Surgery and Radiology, University of Vermont,
Burlington, Vt (B.L.S.); Department of Radiology, University of Washington,
Seattle Cancer Care Alliance Seattle, Wash (J.M.L.); Department of Radiology,
Massachusetts General Hospital, Boston, Mass (C.D.L.); Department of Public
Health Sciences, University of California, Davis, Davis, Calif (D.L.M.)
| | - Louise M. Henderson
- From the Kaiser Permanente Washington Health Research Institute, 1730
Minor Ave, Suite 1600, Seattle, WA 98101 (K.J.W., L.I., D.S.M.B., S.D.B., M.B.,
D.J., D.L.M.); Departments of Medicine and Epidemiology and Biostatistics,
General Internal Medicine Section, Department of Veterans Affairs, University of
California, San Francisco, San Francisco, Calif (K.K.); Department of Radiology,
University of North Carolina, Chapel Hill, NC (L.M.H.); Department of Medicine,
Brigham and Women’s Hospital, Boston, Mass (L.N.); Department of
Biomedical Data Science, Norris Cotton Cancer Center, Dartmouth Medical School,
Hanover, NH (T.O.); Departments of Surgery and Radiology, University of Vermont,
Burlington, Vt (B.L.S.); Department of Radiology, University of Washington,
Seattle Cancer Care Alliance Seattle, Wash (J.M.L.); Department of Radiology,
Massachusetts General Hospital, Boston, Mass (C.D.L.); Department of Public
Health Sciences, University of California, Davis, Davis, Calif (D.L.M.)
| | - Larissa Nekhlyudov
- From the Kaiser Permanente Washington Health Research Institute, 1730
Minor Ave, Suite 1600, Seattle, WA 98101 (K.J.W., L.I., D.S.M.B., S.D.B., M.B.,
D.J., D.L.M.); Departments of Medicine and Epidemiology and Biostatistics,
General Internal Medicine Section, Department of Veterans Affairs, University of
California, San Francisco, San Francisco, Calif (K.K.); Department of Radiology,
University of North Carolina, Chapel Hill, NC (L.M.H.); Department of Medicine,
Brigham and Women’s Hospital, Boston, Mass (L.N.); Department of
Biomedical Data Science, Norris Cotton Cancer Center, Dartmouth Medical School,
Hanover, NH (T.O.); Departments of Surgery and Radiology, University of Vermont,
Burlington, Vt (B.L.S.); Department of Radiology, University of Washington,
Seattle Cancer Care Alliance Seattle, Wash (J.M.L.); Department of Radiology,
Massachusetts General Hospital, Boston, Mass (C.D.L.); Department of Public
Health Sciences, University of California, Davis, Davis, Calif (D.L.M.)
| | - Tracy Onega
- From the Kaiser Permanente Washington Health Research Institute, 1730
Minor Ave, Suite 1600, Seattle, WA 98101 (K.J.W., L.I., D.S.M.B., S.D.B., M.B.,
D.J., D.L.M.); Departments of Medicine and Epidemiology and Biostatistics,
General Internal Medicine Section, Department of Veterans Affairs, University of
California, San Francisco, San Francisco, Calif (K.K.); Department of Radiology,
University of North Carolina, Chapel Hill, NC (L.M.H.); Department of Medicine,
Brigham and Women’s Hospital, Boston, Mass (L.N.); Department of
Biomedical Data Science, Norris Cotton Cancer Center, Dartmouth Medical School,
Hanover, NH (T.O.); Departments of Surgery and Radiology, University of Vermont,
Burlington, Vt (B.L.S.); Department of Radiology, University of Washington,
Seattle Cancer Care Alliance Seattle, Wash (J.M.L.); Department of Radiology,
Massachusetts General Hospital, Boston, Mass (C.D.L.); Department of Public
Health Sciences, University of California, Davis, Davis, Calif (D.L.M.)
| | - Brian L. Sprague
- From the Kaiser Permanente Washington Health Research Institute, 1730
Minor Ave, Suite 1600, Seattle, WA 98101 (K.J.W., L.I., D.S.M.B., S.D.B., M.B.,
D.J., D.L.M.); Departments of Medicine and Epidemiology and Biostatistics,
General Internal Medicine Section, Department of Veterans Affairs, University of
California, San Francisco, San Francisco, Calif (K.K.); Department of Radiology,
University of North Carolina, Chapel Hill, NC (L.M.H.); Department of Medicine,
Brigham and Women’s Hospital, Boston, Mass (L.N.); Department of
Biomedical Data Science, Norris Cotton Cancer Center, Dartmouth Medical School,
Hanover, NH (T.O.); Departments of Surgery and Radiology, University of Vermont,
Burlington, Vt (B.L.S.); Department of Radiology, University of Washington,
Seattle Cancer Care Alliance Seattle, Wash (J.M.L.); Department of Radiology,
Massachusetts General Hospital, Boston, Mass (C.D.L.); Department of Public
Health Sciences, University of California, Davis, Davis, Calif (D.L.M.)
| | - Janie M. Lee
- From the Kaiser Permanente Washington Health Research Institute, 1730
Minor Ave, Suite 1600, Seattle, WA 98101 (K.J.W., L.I., D.S.M.B., S.D.B., M.B.,
D.J., D.L.M.); Departments of Medicine and Epidemiology and Biostatistics,
General Internal Medicine Section, Department of Veterans Affairs, University of
California, San Francisco, San Francisco, Calif (K.K.); Department of Radiology,
University of North Carolina, Chapel Hill, NC (L.M.H.); Department of Medicine,
Brigham and Women’s Hospital, Boston, Mass (L.N.); Department of
Biomedical Data Science, Norris Cotton Cancer Center, Dartmouth Medical School,
Hanover, NH (T.O.); Departments of Surgery and Radiology, University of Vermont,
Burlington, Vt (B.L.S.); Department of Radiology, University of Washington,
Seattle Cancer Care Alliance Seattle, Wash (J.M.L.); Department of Radiology,
Massachusetts General Hospital, Boston, Mass (C.D.L.); Department of Public
Health Sciences, University of California, Davis, Davis, Calif (D.L.M.)
| | - Constance D. Lehman
- From the Kaiser Permanente Washington Health Research Institute, 1730
Minor Ave, Suite 1600, Seattle, WA 98101 (K.J.W., L.I., D.S.M.B., S.D.B., M.B.,
D.J., D.L.M.); Departments of Medicine and Epidemiology and Biostatistics,
General Internal Medicine Section, Department of Veterans Affairs, University of
California, San Francisco, San Francisco, Calif (K.K.); Department of Radiology,
University of North Carolina, Chapel Hill, NC (L.M.H.); Department of Medicine,
Brigham and Women’s Hospital, Boston, Mass (L.N.); Department of
Biomedical Data Science, Norris Cotton Cancer Center, Dartmouth Medical School,
Hanover, NH (T.O.); Departments of Surgery and Radiology, University of Vermont,
Burlington, Vt (B.L.S.); Department of Radiology, University of Washington,
Seattle Cancer Care Alliance Seattle, Wash (J.M.L.); Department of Radiology,
Massachusetts General Hospital, Boston, Mass (C.D.L.); Department of Public
Health Sciences, University of California, Davis, Davis, Calif (D.L.M.)
| | - Diana L. Miglioretti
- From the Kaiser Permanente Washington Health Research Institute, 1730
Minor Ave, Suite 1600, Seattle, WA 98101 (K.J.W., L.I., D.S.M.B., S.D.B., M.B.,
D.J., D.L.M.); Departments of Medicine and Epidemiology and Biostatistics,
General Internal Medicine Section, Department of Veterans Affairs, University of
California, San Francisco, San Francisco, Calif (K.K.); Department of Radiology,
University of North Carolina, Chapel Hill, NC (L.M.H.); Department of Medicine,
Brigham and Women’s Hospital, Boston, Mass (L.N.); Department of
Biomedical Data Science, Norris Cotton Cancer Center, Dartmouth Medical School,
Hanover, NH (T.O.); Departments of Surgery and Radiology, University of Vermont,
Burlington, Vt (B.L.S.); Department of Radiology, University of Washington,
Seattle Cancer Care Alliance Seattle, Wash (J.M.L.); Department of Radiology,
Massachusetts General Hospital, Boston, Mass (C.D.L.); Department of Public
Health Sciences, University of California, Davis, Davis, Calif (D.L.M.)
| |
Collapse
|
14
|
Pan B, Xu Y, Zhou YD, Yao R, Wu HW, Zhu QL, Wang CJ, Mao F, Lin Y, Shen SJ, Sun Q. The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: A meta-analysis of studies from recent decade (2008-2018). Cancer Med 2019; 8:2908-2918. [PMID: 31038845 PMCID: PMC6558468 DOI: 10.1002/cam4.2198] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2019] [Revised: 03/18/2019] [Accepted: 04/10/2019] [Indexed: 01/04/2023] Open
Abstract
Background The incidence of bilateral breast cancer (BBC) is increasing nowadays comprising 2%‐11% of all breast cancer (BC). According to the interval time between the first and second cancer, BBC could be divided into synchronous (SBBC) and metachronous (MBBC). However, this interval time is quite different across studies. It remains controversial whether the survival of BBC, SBBC, and MBBC is similar or worse compared to that of unilateral breast cancer (UBC), and whether the survival of SBBC is similar or worse compared to MBBC. To better understand the survival of UBC, BBC, SBBC, and MBBC and how the interval time would influence the prognosis of SBBC and MBBC, we performed this meta‐analysis on studies from recent 10 years (2008‐2018). Methods Databases of PubMed, Embase, and Web of Science were searched for relevant studies within recent 10 years. Hazard ratio (HR) was adopted to evaluate the difference of overall survival (OS) of UBC, BBC, SBBC, and MBBC. HR of OS comparisons were performed between BBC vs UBC, SBBC vs UBC, MBBC vs UBC, and SBBC vs MBBC with 3, 6, 12 months as the interval time, respectively. Results There were 15 studies of 72 302 UBC and 2912 BBC included in the meta‐analysis. The summary HR of OS comparison between BBC vs UBC was 1.68 (95% CI: 1.28‐2.20), SBBC vs UBC was 2.01 (95% CI: 1.14‐3.55), MBBC vs UBC was 3.22 (95% CI: 0.75‐13.78). When 3, 6, 12 months were used as the interval time, the summary HR of the OS comparison between of SBBC vs MBBC were 0.64 (95% CI: 0.44‐0.94), 1.17 (95% CI: 0.84‐1.63) and 1.45 (95% CI: 1.10‐1.92), respectively. Conclusion BBC and SBBC showed worse prognosis in terms of OS compared to UBC while MBBC manifested similar or non‐superior survival as UBC. The OS comparison between SBBC and MBBC changed with different interval time used. The longer the interval time used, the worse the survival of SBBC. SBBC with interval of 3‐12 months between the two cancers had the worst prognosis. When 6 months was used to differentiate SBBC from MBBC, these two clinical entities showed similar OS.
Collapse
Affiliation(s)
- Bo Pan
- Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China
| | - Ying Xu
- Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China
| | - Yi-Dong Zhou
- Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China
| | - Ru Yao
- Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China
| | - Huan-Wen Wu
- Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China
| | - Qing-Li Zhu
- Department of Ultrasound, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China
| | - Chang-Jun Wang
- Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China
| | - Feng Mao
- Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China
| | - Yan Lin
- Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China
| | - Song-Jie Shen
- Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China
| | - Qiang Sun
- Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China
| |
Collapse
|
15
|
Aarts AMWM, Duffy SW, Geurts SME, Vulkan DP, Houssami N, Zappa M, Nagtegaal ID, Verbeek ALM, Broeders MJM. Towards evidence-based follow-up intervals for breast cancer survivors: Estimates of the preclinical detectable phase of contralateral second breast cancer. Breast 2019; 45:70-74. [PMID: 30884341 DOI: 10.1016/j.breast.2019.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2018] [Revised: 03/01/2019] [Accepted: 03/07/2019] [Indexed: 11/16/2022] Open
Abstract
PURPOSE Follow-up schemes in breast cancer survivors are predominantly consensus-based. To determine evidence-based follow-up intervals, estimates of sensitivity of the screening test(s) and duration of the preclinical detectable phase (PCDP) are key. We estimated the sensitivity and the duration of the PCDP of clinical breast examination (CBE) and mammography for the detection of contralateral second breast cancers (CBC) in breast cancer survivors. METHODS Women with a CBC (N = 589) diagnosed in Florence between 1980 and 2005 were included. Test sensitivity and the duration of PCDP were estimated using a simple exponential model of PCDP duration. Analyses were stratified by follow-up period (0-5 vs. >5 years after primary diagnosis) and age at CBC diagnosis (<50 vs. ≥50 years). RESULTS For CBE, test sensitivity was 55% and the duration of the PCDP 16 months. Mammography sensitivity was 91% and duration of the PCDP 35 months. Stratified analyses showed a higher test sensitivity for CBE for women aged <50 (70% vs. 51%). No difference in the duration of PCDP of CBE was found. For mammography, test sensitivity and the duration of the PCDP were higher for women with longer follow-up and in older women. CONCLUSIONS Poor test sensitivity for CBE with a shorter duration of the PCDP compared with mammography were observed. Mammography had high test sensitivity and the potential to detect CBCs early. The estimated duration of the PCDP (35 months) was considerably longer than the recommended follow-up interval (12 months). Future studies are needed to determine whether a longer follow-up interval is appropriate.
Collapse
Affiliation(s)
- A M W M Aarts
- Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands.
| | - S W Duffy
- Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | - S M E Geurts
- Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands
| | - D P Vulkan
- Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | - N Houssami
- Sydney School of Public Health, Sydney Medical School, The University of Sydney, Sydney, Australia
| | - M Zappa
- Instituto per Lo Studio e La Prevenzione Oncologica (ISPO), Florence, Italy
| | - I D Nagtegaal
- Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands
| | - A L M Verbeek
- Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands
| | - M J M Broeders
- Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands; Dutch Expert Centre for Screening, Nijmegen, the Netherlands
| |
Collapse
|
16
|
Sim Y, Tan VKM, Sidek NAB, Chia DKA, Tan BKT, Madhukumar P, Yong WS, Wong CY, Ong KW. Bilateral breast cancers in an Asian population, and a comparison between synchronous and metachronous tumours. ANZ J Surg 2018; 88:982-987. [PMID: 30141242 DOI: 10.1111/ans.14773] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2018] [Accepted: 06/17/2018] [Indexed: 11/29/2022]
Abstract
BACKGROUND Women with unilateral breast cancer have an increased risk of developing bilateral breast cancer (BBC). Patients with metachronous BBC (mBBC) usually have an earlier age of onset, and their prognoses have been shown to be either similar or poorer than those with synchronous BBC (sBBC). Given the differing presentation and characteristics of breast cancers in the Asian population and the West, this study aims to characterize Asian patients with BBC. METHODS All patients who had oncological breast surgery between 2001 and 2010 at the Singapore General Hospital and National Cancer Centre Singapore were reviewed. Patients with BBC were identified and studied. RESULTS A total of 5520 Singaporean women had oncological breast surgery, 155 women (2.8%) had BBC. Of those with BBC, 47.1% (n = 73) were synchronous and 52.9% (n = 82) metachronous (mean interval of 39.4 months), and there was no difference in median age in both groups (54 years of age). Patients with sBBC were more likely to have a positive family history and had asymptomatic contralateral tumours. Although patients with sBBCs were more likely to have ER/PR positive and Her2 negative tumours, they had a lower 5-year overall survival than those with mBBC (P = 0.022). CONCLUSION Our study shows that Asian women with BBC have different characteristics to their Western counterparts. In particular, women with sBBC tended to have a lower 5-year overall survival compared to those with mBBC, despite having seemingly biologically favourable tumours, which suggest that there may be more underlying their tumour biology and genetics.
Collapse
Affiliation(s)
- Yirong Sim
- Department of Surgical Oncology, National Cancer Centre Singapore, Singapore.,Singhealth Duke-NUS Breast Centre, Singapore General Hospital, Singapore
| | - Veronique K M Tan
- Department of Surgical Oncology, National Cancer Centre Singapore, Singapore.,Singhealth Duke-NUS Breast Centre, Singapore General Hospital, Singapore
| | - Nur A B Sidek
- Singhealth Duke-NUS Breast Centre, Singapore General Hospital, Singapore
| | - Daryl K A Chia
- Singhealth Duke-NUS Breast Centre, Singapore General Hospital, Singapore
| | - Benita K T Tan
- Singhealth Duke-NUS Breast Centre, Singapore General Hospital, Singapore
| | - Preetha Madhukumar
- Department of Surgical Oncology, National Cancer Centre Singapore, Singapore.,Singhealth Duke-NUS Breast Centre, Singapore General Hospital, Singapore
| | - Wei Sean Yong
- Department of Surgical Oncology, National Cancer Centre Singapore, Singapore.,Singhealth Duke-NUS Breast Centre, Singapore General Hospital, Singapore
| | - Chow Yin Wong
- Singhealth Duke-NUS Breast Centre, Singapore General Hospital, Singapore
| | - Kong Wee Ong
- Department of Surgical Oncology, National Cancer Centre Singapore, Singapore.,Singhealth Duke-NUS Breast Centre, Singapore General Hospital, Singapore
| |
Collapse
|
17
|
Houssami N, Cho N. Screening women with a personal history of breast cancer: overview of the evidence on breast imaging surveillance. Ultrasonography 2018; 37:277-287. [PMID: 30056638 PMCID: PMC6177686 DOI: 10.14366/usg.18017] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2018] [Accepted: 06/07/2018] [Indexed: 12/25/2022] Open
Abstract
This work reviews the evidence on breast imaging for screening (surveillance) in women with a history of breast cancer (BC). Early detection of second BCs in these women improves their prognosis based on studies using mammography (usually with clinical examinations) for surveillance. Cohort studies have estimated that mammography surveillance has moderate sensitivity (65.4%) and good specificity (98.3%), and have shown that these women are at a higher risk of interval BC than age- and breast density-matched women without a history of BC. Studies of adjunct imaging (ultrasound, magnetic resonance imaging) for surveillance that have reported detection and accuracy measures have generally shown that adjunct imaging detected more second BCs than mammography and added substantially to the amount of false-positive results; however, little evidence exists regarding screening efficacy of adjunct imaging as part of routine surveillance.
Collapse
Affiliation(s)
- Nehmat Houssami
- Sydney School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia
| | - Nariya Cho
- Department of Radiology, Seoul National University Hospital, Seoul, Korea
| |
Collapse
|
18
|
Abstract
OBJECTIVE Current clinical guidelines are consistent in supporting annual mammography for women after treatment of primary breast cancer. Surveillance imaging beyond standard digital mammography, including digital breast tomosynthesis (DBT), breast ultrasound, and MRI, may improve outcomes. This article reviews the evidence on the performance and effectiveness of breast imaging modalities available for surveillance after treatment of sporadic unilateral primary breast cancer and identifies additional factors to be considered when selecting an imaging surveillance regimen. CONCLUSION Evidence review supports the use of mammography for surveillance after primary breast cancer treatment. Variability exists in guideline recommendations for surveillance initiation, interval, and cessation. DBT offers the most promise as a potential modality to replace standard digital mammography as a front-line surveillance test; a single published study to date has shown a significant decrease in recall rates compared with standard digital mammography alone. Most guidelines do not support the use of whole-breast ultrasound in breast cancer surveillance, and further studies are needed to define the characteristics of women who may benefit from MRI surveillance. The emerging evidence about surveillance imaging outcomes suggests that additional factors, including patient and imaging characteristics, tumor biology and gene expression profile, and choice of treatment, warrant consideration in selecting personalized posttreatment imaging surveillance regimens.
Collapse
Affiliation(s)
- Diana L Lam
- 1 Department of Radiology, University of Washington School of Medicine, Seattle Cancer Care Alliance, 825 Eastlake Ave East, G2-600, Seattle, WA 98109-1023
| | - Nehmat Houssami
- 2 Screening and Test Evaluation Program, Sydney School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia
| | - Janie M Lee
- 1 Department of Radiology, University of Washington School of Medicine, Seattle Cancer Care Alliance, 825 Eastlake Ave East, G2-600, Seattle, WA 98109-1023
| |
Collapse
|
19
|
Bychkovsky BL, Lin NU. Imaging in the evaluation and follow-up of early and advanced breast cancer: When, why, and how often? Breast 2016; 31:318-324. [PMID: 27422453 DOI: 10.1016/j.breast.2016.06.017] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2016] [Accepted: 06/16/2016] [Indexed: 11/15/2022] Open
Abstract
Imaging in the evaluation and follow-up of patients with early or advanced breast cancer is an important aspect of cancer care. The role of imaging in breast cancer depends on the goal and should only be performed to guide clinical decisions. Imaging is valuable if a finding will change the course of treatment and improve outcomes, whether this is disease-free survival, overall survival or quality-of-life. In the last decade, imaging is often overused in oncology and contributes to rising healthcare costs. In this context, we review the data that supports the appropriate use of imaging for breast cancer patients. We will discuss: 1) the optimal use of staging imaging in both early (Stage 0-II) and locally advanced (Stage III) breast cancer, 2) the role of surveillance imaging to detect recurrent disease in Stage 0-III breast cancer and 3) how patients with metastatic breast cancer should be followed with advanced imaging.
Collapse
Affiliation(s)
- Brittany L Bychkovsky
- Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
| | - Nancy U Lin
- Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
| |
Collapse
|
20
|
Jobsen JJ, van der Palen J, Ong F, Riemersma S, Struikmans H. Bilateral breast cancer, synchronous and metachronous; differences and outcome. Breast Cancer Res Treat 2015; 153:277-83. [DOI: 10.1007/s10549-015-3538-5] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2015] [Accepted: 08/10/2015] [Indexed: 10/23/2022]
|
21
|
O'Brien JA, Ho A, Wright GP, Stempel M, Patil S, Krause K, Morrow M, Gemignani ML. Breast-Conserving Surgery in Bilateral Breast Cancer. Ann Surg Oncol 2015; 22:3389-96. [PMID: 26265365 DOI: 10.1245/s10434-015-4746-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2014] [Indexed: 02/04/2023]
Abstract
BACKGROUND Bilateral breast cancer (BBC) may present as synchronous (SBC) or metachronous breast cancer (MBC). Optimal surgical management of BBC patients is not well-defined. In this study, we report on histopathology, treatment, and outcomes in BBC patients. METHODS Upon Institutional Review Board approval, we identified BBC patients diagnosed and treated for invasive breast cancer between 1999 and 2007. Retrospective chart review for demographics, histopathology, treatment, and outcomes was performed, and factors associated with BCS choice were collected. Contraindication to BCS was defined as any of the following one-breast findings: multicentric disease, tumor considered too large for BCS, and a patient without a nominal breast size for acceptable cosmetic results. McNemar's test for matched pairs (binary variables) or the paired t test (continuous variables) were used to examine if a pathologic characteristic differed within a cancer pair. Kaplan-Meier methods estimated overall survival (OS). RESULTS A total of 203 BBC patients (119 SBC, 84 MBC) comprised our study group. Histopathologic characteristics of the first and second cancers diagnosed in both the SBC and MBC patients were very similar in histologic type and molecular profiles. Overall, 57% of MBC patients underwent breast-conserving surgery (BCS) at initial diagnosis versus 34% of patients with SBC. BCS contraindications were similar in both groups: 16 (34%) MBC patients and 28 (36%) SBC patients. Kaplan-Meier OS estimates at 5 and 10 years were 86 and 78% for MBC, and 87 and 77% for SBC patients, respectively. CONCLUSIONS OS was excellent for both the MBC and SBC groups. Contraindications to BCS did not differ between groups. However, patients with SBC were less likely to undergo BCS compared with patients with MBC at the time of initial diagnosis.
Collapse
Affiliation(s)
- Julie A O'Brien
- Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Lee JM, Buist DSM, Houssami N, Dowling EC, Halpern EF, Gazelle GS, Lehman CD, Henderson LM, Hubbard RA. Five-year risk of interval-invasive second breast cancer. J Natl Cancer Inst 2015; 107:djv109. [PMID: 25904721 PMCID: PMC4651041 DOI: 10.1093/jnci/djv109] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2014] [Revised: 11/07/2014] [Accepted: 03/23/2015] [Indexed: 03/25/2024] Open
Abstract
BACKGROUND Earlier detection of second breast cancers after primary breast cancer (PBC) treatment improves survival, yet mammography is less accurate in women with prior breast cancer. The purpose of this study was to examine women presenting clinically with second breast cancers after negative surveillance mammography (interval cancers), and to estimate the five-year risk of interval-invasive second cancers for women with varying risk profiles. METHODS We evaluated a prospective cohort of 15 114 women with 47 717 surveillance mammograms diagnosed with stage 0-II unilateral PBC from 1996 through 2008 at facilities in the Breast Cancer Surveillance Consortium. We used discrete time survival models to estimate the association between odds of an interval-invasive second breast cancer and candidate predictors, including demographic, PBC, and imaging characteristics. All statistical tests were two-sided. RESULTS The cumulative incidence of second breast cancers after five years was 54.4 per 1000 women, with 325 surveillance-detected and 138 interval-invasive second breast cancers. The five-year risk of interval-invasive second cancer for women with referent category characteristics was 0.60%. For women with the most and least favorable profiles, the five-year risk ranged from 0.07% to 6.11%. Multivariable modeling identified grade II PBC (odds ratio [OR] = 1.95, 95% confidence interval [CI] = 1.15 to 3.31), treatment with lumpectomy without radiation (OR = 3.27, 95% CI = 1.91 to 5.62), interval PBC presentation (OR = 2.01, 95% CI 1.28 to 3.16), and heterogeneously dense breasts on mammography (OR = 1.54, 95% CI = 1.01 to 2.36) as independent predictors of interval-invasive second breast cancers. CONCLUSIONS PBC diagnosis and treatment characteristics contribute to variation in subsequent-interval second breast cancer risk. Consideration of these factors may be useful in developing tailored post-treatment imaging surveillance plans.
Collapse
MESH Headings
- Adult
- Aged
- Breast/pathology
- Breast Neoplasms/diagnostic imaging
- Breast Neoplasms/epidemiology
- Breast Neoplasms/pathology
- Breast Neoplasms/therapy
- Carcinoma, Intraductal, Noninfiltrating/diagnostic imaging
- Carcinoma, Intraductal, Noninfiltrating/epidemiology
- Carcinoma, Intraductal, Noninfiltrating/pathology
- Carcinoma, Intraductal, Noninfiltrating/therapy
- Early Detection of Cancer/methods
- Female
- Humans
- Incidence
- Mammography
- Mass Screening/methods
- Middle Aged
- Neoplasm Grading
- Neoplasm Invasiveness
- Neoplasm Staging
- Neoplasms, Second Primary/diagnostic imaging
- Neoplasms, Second Primary/epidemiology
- Neoplasms, Second Primary/pathology
- Neoplasms, Second Primary/therapy
- North Carolina/epidemiology
- Odds Ratio
- Population Surveillance
- Prospective Studies
- Registries
- Risk Assessment
- Risk Factors
- Time Factors
- Washington/epidemiology
Collapse
Affiliation(s)
- Janie M Lee
- Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA (JML, CDL); Department of Radiology and Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA (JML, ECD, EFH, GSG); Group Health Research Institute, Group Health Cooperative, Seattle, WA (DSMB, RAH); Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia (NH); Department of Radiology, University of North Carolina, Chapel Hill, NC (LMH).
| | - Diana S M Buist
- Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA (JML, CDL); Department of Radiology and Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA (JML, ECD, EFH, GSG); Group Health Research Institute, Group Health Cooperative, Seattle, WA (DSMB, RAH); Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia (NH); Department of Radiology, University of North Carolina, Chapel Hill, NC (LMH)
| | - Nehmat Houssami
- Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA (JML, CDL); Department of Radiology and Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA (JML, ECD, EFH, GSG); Group Health Research Institute, Group Health Cooperative, Seattle, WA (DSMB, RAH); Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia (NH); Department of Radiology, University of North Carolina, Chapel Hill, NC (LMH)
| | - Emily C Dowling
- Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA (JML, CDL); Department of Radiology and Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA (JML, ECD, EFH, GSG); Group Health Research Institute, Group Health Cooperative, Seattle, WA (DSMB, RAH); Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia (NH); Department of Radiology, University of North Carolina, Chapel Hill, NC (LMH)
| | - Elkan F Halpern
- Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA (JML, CDL); Department of Radiology and Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA (JML, ECD, EFH, GSG); Group Health Research Institute, Group Health Cooperative, Seattle, WA (DSMB, RAH); Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia (NH); Department of Radiology, University of North Carolina, Chapel Hill, NC (LMH)
| | - G Scott Gazelle
- Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA (JML, CDL); Department of Radiology and Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA (JML, ECD, EFH, GSG); Group Health Research Institute, Group Health Cooperative, Seattle, WA (DSMB, RAH); Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia (NH); Department of Radiology, University of North Carolina, Chapel Hill, NC (LMH)
| | - Constance D Lehman
- Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA (JML, CDL); Department of Radiology and Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA (JML, ECD, EFH, GSG); Group Health Research Institute, Group Health Cooperative, Seattle, WA (DSMB, RAH); Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia (NH); Department of Radiology, University of North Carolina, Chapel Hill, NC (LMH)
| | - Louise M Henderson
- Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA (JML, CDL); Department of Radiology and Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA (JML, ECD, EFH, GSG); Group Health Research Institute, Group Health Cooperative, Seattle, WA (DSMB, RAH); Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia (NH); Department of Radiology, University of North Carolina, Chapel Hill, NC (LMH)
| | - Rebecca A Hubbard
- Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA (JML, CDL); Department of Radiology and Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA (JML, ECD, EFH, GSG); Group Health Research Institute, Group Health Cooperative, Seattle, WA (DSMB, RAH); Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia (NH); Department of Radiology, University of North Carolina, Chapel Hill, NC (LMH)
| |
Collapse
|
23
|
Yoon JH, Kim MJ, Kim EK, Moon HJ. Imaging surveillance of patients with breast cancer after primary treatment: current recommendations. Korean J Radiol 2015; 16:219-28. [PMID: 25741186 PMCID: PMC4347260 DOI: 10.3348/kjr.2015.16.2.219] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2014] [Accepted: 11/24/2014] [Indexed: 11/29/2022] Open
Abstract
Women who have been treated for breast cancer are at risk for second breast cancers, such as ipsilateral recurrence or contralateral metachronous breast cancer. As the number of breast cancer survivors increases, interest in patient management and surveillance after treatment has also increased. However, post-treatment surveillance programs for patients with breast cancer have not been firmly established. In this review, we focus on the imaging modalities that have been used in post-treatment surveillance for patients with breast cancer, such as mammography, ultrasonography, magnetic resonance imaging, and positron emission tomography, the effectiveness of each modality for detecting recurrence, and how they can be applied to manage patients.
Collapse
Affiliation(s)
- Jung Hyun Yoon
- Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul 120-752, Korea
| | - Min Jung Kim
- Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul 120-752, Korea
| | - Eun-Kyung Kim
- Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul 120-752, Korea
| | - Hee Jung Moon
- Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul 120-752, Korea
| |
Collapse
|
24
|
Synchronous and metachronous breast malignancies: a cross-sectional retrospective study and review of the literature. BIOMED RESEARCH INTERNATIONAL 2014; 2014:250727. [PMID: 24877073 PMCID: PMC4022260 DOI: 10.1155/2014/250727] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/03/2013] [Accepted: 02/22/2014] [Indexed: 11/17/2022]
Abstract
Objective. There is increasing interest in patients with metachronous (MBC) and synchronous breast cancer (SBC). The objective of this study was to evaluate the occurrence and outcome of MBCs and SBCs. Methods. A retrospective study on women operated in our department for breast cancer between 2002 and 2005 was carried out. Patients were divided into three groups: women with MBC, SBC, and unilateral breast cancer (UBC). Moreover, we performed a meta-analysis of the English literature about multiple breast cancers between 2000 and 2011 taking into consideration their prevalence and overall survival (OS). Results. We identified 584 breast cancer patients: 16 women (3%) presented SBC and 40 MBC (7%, second cancer after 72-month follow-up IQR 40–145). Although the meta-analysis showed significant OS differences between MBC or SBC and UBC, we did not observe any significant OS difference among the three groups of our population. Anyway, we found a significant worse disease-free survival in MBC than UBC and a significant higher prevalence of radical surgery in MBC and SBC than UBC. Conclusions. Despite the low prevalence of MBC and SBC, the presence of a long time risk of MBC confirms the crucial role of ipsi- and contralateral mammographies in the postoperative follow-up.
Collapse
|
25
|
Doutriaux-Dumoulin I, Meingan P. Surveillance des cancers du sein : doit-on adapter le suivi selon l’âge ? La femme âgée. IMAGERIE DE LA FEMME 2013. [DOI: 10.1016/j.femme.2013.03.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
26
|
Suh YJ, Kim MJ, Kim EK, Moon HJ, Kim SI, Park BW. Value of ultrasound for postoperative surveillance of asian patients with history of breast cancer surgery: a single-center study. Ann Surg Oncol 2013; 20:3461-8. [PMID: 23695431 DOI: 10.1245/s10434-013-3020-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2012] [Indexed: 11/18/2022]
Abstract
PURPOSE To assess the diagnostic performance of postoperative ultrasound (US) surveillance for the detection of malignant lesions and to evaluate the clinical role of US in the postoperative surveillance of patients with breast cancer history. METHODS We studied a total of 390 patients who underwent surgery for breast cancer between January 2000 and December 2002, 286 mastectomy patients, 103 breast conservation surgery (BCS) patients, and one with both mastectomy and BCS. A total of 4,081 US examinations by December 2010 were reviewed. The final diagnosis for final-positive lesions was based on cytopathology results, clinical follow-up, and imaging studies. Diagnostic performances for detecting final-positive lesions were assessed. We also compared the frequency of distant metastases in patients with final-positive findings and those without. The overall survival was estimated. RESULTS Among 2,925 examinations in 287 patients with mastectomy, there were 85 US-positive and 23 final-positive lesions (27 %) in 20 patients at final diagnosis. Among 1,171 examinations in 104 BCS patients, there were 32 US-positive and five final-positive (15.6 %) findings in four patients. The sensitivity, specificity, positive predictive value, and accuracy of US for final-positive lesions after breast cancer surgery were 95.8,97.8, 27.1, and 97.9 % in mastectomy patients and 42.9, 97.5, 9.4, and 97.2 % in BCS patients. Among mastectomy patients, patients with final-positive findings had a higher incidence of distant metastasis than patients without final-positive findings (31.6 vs. 9.3 %, p = 0.01). Among BCS patients, there was no distant metastasis. Among mastectomy patients, the overall survival was not significantly different between patients with only final-positive findings and in patients with final-positive findings and distant metastasis (p > 0.05). CONCLUSIONS Postoperative US had a high sensitivity for the detection of malignant lesions in the breast and the regional area, which can be a predictor of distant metastasis in mastectomy patients; however, the role of postoperative US in the detection of malignant lesions in BCS patients is unclear.
Collapse
Affiliation(s)
- Young Joo Suh
- Department of Radiology, Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
| | | | | | | | | | | |
Collapse
|
27
|
Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, Francis PA, Kyriakides S, Pagani O, Senkus E, Costa A, Winer EP. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast 2013; 22:203-10. [PMID: 23601761 DOI: 10.1016/j.breast.2013.03.006] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2013] [Accepted: 03/13/2013] [Indexed: 12/17/2022] Open
Abstract
In clinical practice, the surveillance and follow-up of patients with breast cancer (BC) is quite variable. At the 7th European Breast Cancer Conference, the ESO-MBC Task Force convened a series of lectures, followed by open debate, on the use of physical examination, imaging, and laboratory tests in patients with early-stage BC, and for restaging evaluations and follow-up among patients with MBC. Based on the available data, the Task Force recommends against intensive, routine radiologic or blood-based surveillance (with the exception of mammography) in patients with early-stage BC. As systemic therapies for MBC continue to improve, this question might be re-visited in the context of a carefully controlled clinical trial in specific BC subtypes. For patients with MBC, response to therapy should generally be assessed 2-3 months after initiation of treatment, and thereafter every 2-4 months for endocrine therapy or every 2-4 cycles for chemotherapy, depending on the dynamics of the disease, the location and extent of metastatic involvement, and type of treatment. Additional testing should be performed irrespective of the planned intervals if progression of disease is suspected (e.g. in the case of specific symptoms). Use of tumor markers is not recommended for surveillance of early-stage patients, but may be helpful in monitoring response to therapy in patients with metastatic disease. However, change in tumor markers alone should not be used for decision-making. Moving forward, enhanced efforts to document quality of life over time should be made in order to more fully evaluate the risk/benefit ratio of available options.
Collapse
Affiliation(s)
- Nancy U Lin
- Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, 450 Brookline Avenue, Boston, MA 02215, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Lowery JT, Risendal BC. A population perspective to mitigating risk for second primary breast cancer. BREAST CANCER MANAGEMENT 2013. [DOI: 10.2217/bmt.13.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
SUMMARY There are more than 2 million breast cancer survivors in the USA. Approximately 5–10% of survivors will develop a second, metachronous breast cancer within 10 years’ time; a risk two- to six-times higher than that in the general population. Women who develop metachronous cancer are more likely to die from the disease compared with women with unilateral cancer. Risk factors for metachronous cancer include BRCA mutation status, young age, family history and tumor phenotype, while adjuvant chemotherapy and endocrine therapy may attenuate the risk. Surveillance guidelines recommend annual mammography, but MRI is not currently indicated for most women. An increasing number of women are choosing prophylactic contralateral mastectomy, although it is not likely to be beneficial for most women. Improved strategies are needed for identifying survivors at an increased risk in order to help guide clinical decisions regarding follow-up care. This review presents an overview of the burden and risk factors for metachronous breast cancer and discusses challenges and opportunities for a population approach to mitigating risk and adverse outcomes from these cancers.
Collapse
Affiliation(s)
- Jan T Lowery
- University of Colorado, School of Public Health, Department of Epidemiology, 13001 E 17th Place, Aurora, CO 80045, USA
- University of Colorado Cancer Center, 13001 E 17th Place, Aurora, CO 80045, USA
| | - Betsy C Risendal
- University of Colorado Cancer Center, 13001 E 17th Place, Aurora, CO 80045, USA
- University of Colorado, School of Public Health, Department of Community & Behavioral Health, 13001 E 17th Place, Aurora, CO 80045, USA
| |
Collapse
|
29
|
Houssami N, Tresham JJ, Fritschi L, Wylie LE. BreastScreen‐based mammography screening in women with a personal history of breast cancer, Western Australian study. Med J Aust 2011; 195:460-4. [DOI: 10.5694/mja11.10702] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Nehmat Houssami
- Screening and Test Evaluation Program, School of Public Health, University of Sydney, Sydney, NSW
| | | | - Lin Fritschi
- Western Australian Institute for Medical Research, University of Western Australia, Perth, WA
| | - Liz E Wylie
- BreastScreen WA, Department of Health, Perth, WA
- Royal Perth Hospital Radiology Department, University of Western Australia, Perth, WA
| |
Collapse
|
30
|
Fisher CS, Wachtel MS, Margenthaler JA. Outcomes for Patients who Develop Both Breast and Colorectal Cancer. Ann Surg Oncol 2011; 19:242-8. [DOI: 10.1245/s10434-011-1843-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2011] [Indexed: 11/18/2022]
|
31
|
Taylor L, Basro S, Apffelstaedt JP, Baatjes K. Time for a re-evaluation of mammography in the young? Results of an audit of mammography in women younger than 40 in a resource restricted environment. Breast Cancer Res Treat 2011; 129:99-106. [PMID: 21698411 DOI: 10.1007/s10549-011-1630-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2010] [Accepted: 06/03/2011] [Indexed: 12/01/2022]
Abstract
Mammography in younger women is considered to be of limited value. In a resource restricted environment without access to magnetic resonance imaging (MRI) and with a high incidence of breast cancer in the young, mammography remains an important diagnostic tool. Recent technical advances and better regulation of mammography make a reassessment of its value in these conditions necessary. Data of all the mammograms performed at a tertiary hospital and private breast clinic between January 2003 and July 2009 in women less than 40 years of age were collected. Indications were the presence of a mass, follow-up after primary cancer therapy, and screening for patients perceived at high risk due to a family history or the presence of atypical hyperplasia. Data acquired were as follows: Demographics, prior breast surgery, indication for mammography, outcome of mammography, diagnostic procedures, and their results. Of 2,167 mammograms, 393 were performed for a palpable mass, diagnostic mammography. In these, the overall cancer detection rate was 40%. If the mammography was reported as breast imaging reporting and data system (BIRADS(®)) 5 versus BIRADS(®) 3 and 4 versus BIRADS(®) 1 and 2, a final diagnosis of malignancy was established in 96, 48, and 5%, respectively. Of 367 mammograms done for the follow-up after primary treatment of breast cancer, seven cancers were diagnosed for a detection rate of 1.9%. Of 1,312 mammograms performed for screening, the recall rate was 4%; the biopsy rate 2%, and the cancer diagnosis rate 3/1,000 examinations. In contrast to past series, this series has shown that recent advances in mammography have made it a useful tool in the management of breast problems in young women, notably in a resource-restricted environment. Women for screening should be selected carefully.
Collapse
Affiliation(s)
- Liezel Taylor
- Medial Faculty, Breast Clinic, University of Stellenbosch, Tygerberg, Cape Town, South Africa
| | | | | | | |
Collapse
|
32
|
Brennan ME, Houssami N. Overview of long term care of breast cancer survivors. Maturitas 2011; 69:106-12. [DOI: 10.1016/j.maturitas.2011.03.010] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2011] [Revised: 03/04/2011] [Accepted: 03/07/2011] [Indexed: 11/26/2022]
|
33
|
Alkner S, Bendahl PO, Fernö M, Manjer J, Rydén L. Prediction of outcome after diagnosis of metachronous contralateral breast cancer. BMC Cancer 2011; 11:114. [PMID: 21450091 PMCID: PMC3080341 DOI: 10.1186/1471-2407-11-114] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2010] [Accepted: 03/30/2011] [Indexed: 11/15/2022] Open
Abstract
Background Although 2-20% of breast cancer patients develop a contralateral breast cancer (CBC), prognosis after CBC is still debated. Using a unique patient cohort, we have investigated whether time interval to second breast cancer (BC2) and mode of detection are associated to prognosis. Methods Information on patient-, tumour-, treatment-characteristics, and outcome was abstracted from patients' individual charts for all patients diagnosed with metachronous CBC in the Southern Healthcare Region of Sweden from 1977-2007. Distant disease-free survival (DDFS) and risk of distant metastases were primary endpoints. Results The cohort included 723 patients with metachronous contralateral breast cancer as primary breast cancer event. Patients with less than three years to BC2 had a significantly impaired DDFS (p = 0.01), and in sub-group analysis, this effect was seen primarily in patients aged <50. By logistic regression analysis, patients diagnosed with BC2 within routine follow-up examinations had a significantly lower risk of developing metastases compared to those who were symptomatic at diagnosis (p < 0.0001). Chemotherapy given after breast BC1 was a negative prognostic factor for DDFS, whereas endocrine treatment and radiotherapy given after BC2 improved DDFS. Conclusions In a large cohort of patients with CBC, we found the time interval to BC2 to be a strong prognostic factor for DDFS in young women and mode of detection to be related to risk of distant metastases. Future studies of tumour biology of BC2 in relation to prognostic factors found in the present study can hopefully provide biological explanations to these findings.
Collapse
Affiliation(s)
- Sara Alkner
- Department of Oncology, Clinical Sciences, Lund, Lund University, Sweden
| | | | | | | | | |
Collapse
|
34
|
Houssami N, Abraham LA, Miglioretti DL, Sickles EA, Kerlikowske K, Buist DSM, Geller BM, Muss HB, Irwig L. Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer. JAMA 2011; 305:790-9. [PMID: 21343578 PMCID: PMC3799940 DOI: 10.1001/jama.2011.188] [Citation(s) in RCA: 117] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
CONTEXT Women with a personal history of breast cancer (PHBC) are at risk of developing another breast cancer and are recommended for screening mammography. Few high-quality data exist on screening performance in PHBC women. OBJECTIVE To examine the accuracy and outcomes of mammography screening in PHBC women relative to screening of similar women without PHBC. DESIGN AND SETTING Cohort of PHBC women, mammogram matched to non-PHBC women, screened through facilities (1996-2007) affiliated with the Breast Cancer Surveillance Consortium. PARTICIPANTS There were 58,870 screening mammograms in 19,078 women with a history of early-stage (in situ or stage I-II invasive) breast cancer and 58,870 matched (breast density, age group, mammography year, and registry) screening mammograms in 55,315 non-PHBC women. MAIN OUTCOME MEASURES Mammography accuracy based on final assessment, cancer detection rate, interval cancer rate, and stage at diagnosis. RESULTS Within 1 year after screening, 655 cancers were observed in PHBC women (499 invasive, 156 in situ) and 342 cancers (285 invasive, 57 in situ) in non-PHBC women. Screening accuracy and outcomes in PHBC relative to non-PHBC women were cancer rates of 10.5 per 1000 screens (95% CI, 9.7-11.3) vs 5.8 per 1000 screens (95% CI, 5.2-6.4), cancer detection rate of 6.8 per 1000 screens (95% CI, 6.2-7.5) vs 4.4 per 1000 screens (95% CI, 3.9-5.0), interval cancer rate of 3.6 per 1000 screens (95% CI, 3.2-4.1) vs 1.4 per 1000 screens (95% CI, 1.1-1.7), sensitivity 65.4% (95% CI, 61.5%-69.0%) vs 76.5% (95% CI, 71.7%-80.7%), specificity 98.3% (95% CI, 98.2%-98.4%) vs 99.0% (95% CI, 98.9%-99.1%), abnormal mammogram results in 2.3% (95% CI, 2.2%-2.5%) vs 1.4% (95% CI, 1.3%-1.5%) (all comparisons P < .001). Screening sensitivity in PHBC women was higher for detection of in situ cancer (78.7%; 95% CI, 71.4%-84.5%) than invasive cancer (61.1%; 95% CI, 56.6%-65.4%), P < .001; lower in the initial 5 years (60.2%; 95% CI, 54.7%-65.5%) than after 5 years from first cancer (70.8%; 95% CI, 65.4%-75.6%), P = .006; and was similar for detection of ipsilateral cancer (66.3%; 95% CI, 60.3%-71.8%) and contralateral cancer (66.1%; 95% CI, 60.9%-70.9%), P = .96. Screen-detected and interval cancers in women with and without PHBC were predominantly early stage. CONCLUSION Mammography screening in PHBC women detects early-stage second breast cancers but has lower sensitivity and higher interval cancer rate, despite more evaluation and higher underlying cancer rate, relative to that in non-PHBC women.
Collapse
Affiliation(s)
- Nehmat Houssami
- Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Synchronous and metachronous bilateral breast cancer: a long-term single-institution experience. Med Oncol 2010; 29:16-24. [DOI: 10.1007/s12032-010-9785-8] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2010] [Accepted: 12/10/2010] [Indexed: 10/18/2022]
|
36
|
Champion L, Brain E, Giraudet AL, Le Stanc E, Wartski M, Edeline V, Madar O, Bellet D, Pecking A, Alberini JL. Breast cancer recurrence diagnosis suspected on tumor marker rising. Cancer 2010; 117:1621-9. [PMID: 21472709 DOI: 10.1002/cncr.25727] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2010] [Revised: 09/02/2010] [Indexed: 01/22/2023]
Affiliation(s)
- Laurence Champion
- Service de Médecine nucléaire, Institut Curie, Hôpital René Huguenin, Saint-Cloud, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Houssami N, Ciatto S. Mammographic surveillance in women with a personal history of breast cancer: how accurate? How effective? Breast 2010; 19:439-45. [PMID: 20547457 DOI: 10.1016/j.breast.2010.05.010] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2010] [Revised: 05/20/2010] [Accepted: 05/20/2010] [Indexed: 10/19/2022] Open
Abstract
We review the accuracy and potential effect of mammography in surveillance of women with a personal history of breast cancer (PHBC). A literature review was performed to identify studies on screening mammography or breast surveillance reporting data on the accuracy or detection capability of mammography, or the effect of early detection of second breast cancers, in women with a PHBC. Evidence on mammography screening in women with PHBC comes from non-randomised studies, and is generally limited by several factors including design limitations. The proportion of ipsilateral breast recurrences detected with mammography ranges between 50% and 80% (including cancers detected also on clinical examination) but is lower at 8%-51% for mammography-only detection. Mammography detects approximately 45%-90% of contralateral cancers. There is evidence of a potential benefit for asymptomatic/early-detected second breast cancers (range of estimated hazard ratios: 0.10-0.86) relative to symptomatic or clinical-detection, in various surveillance strategies that include mammography, however these estimates are likely to have overestimated screening benefit. New evaluations of screening women with a PHBC are needed from screening programs or population datasets, to provide comprehensive measures of screening accuracy and outcomes in this population of women.
Collapse
Affiliation(s)
- Nehmat Houssami
- School of Public Health A27, Sydney Medical School, Edward Ford Building A27, University of Sydney, Sydney, NSW 2006, Australia.
| | | |
Collapse
|